{
    "05Y.DE": {
        "short_name": "VIVORYON THERAPEUTICS",
        "long_name": "Vivoryon Therapeutics N.V.",
        "summary": "Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease; and for the treatment of cancer. Its preclinical development products is PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor for the treatment of cancer. In addition, the company is developing a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Vivoryon Therapeutics AG has a research collaboration agreement with University Medical Center Schleswig-Holstein to discover and develop therapeutics in cancer immunotherapy; collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Halle"
    },
    "05Y.F": {
        "short_name": "VIVORYON THERAPEUTICS",
        "long_name": "Vivoryon Therapeutics N.V.",
        "summary": "Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease; and for the treatment of cancer. Its preclinical development products is PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor for the treatment of cancer. In addition, the company is developing a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Vivoryon Therapeutics AG has a research collaboration agreement with University Medical Center Schleswig-Holstein to discover and develop therapeutics in cancer immunotherapy; collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Halle"
    },
    "0N6.F": {
        "short_name": "NOXXON PH.CONF.IPO EO-,01",
        "long_name": "NOXXON Pharma N.V.",
        "summary": "NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. The company is also developing NOX-E36, which has completed Phase IIa clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Berlin"
    },
    "1846.HK": {
        "short_name": "EUROEYES",
        "long_name": "EuroEyes International Eye Clinic Limited",
        "summary": "EuroEyes International Eye Clinic Limited provides vision correction services in Germany, Denmark, and the People's Republic of China. The company offers refractive laser surgery, which include ReLEx SMILE and FemtoLASIK; phakic lens (ICL) surgery; lens exchange surgery comprising the monofocal and trifocal lens exchange surgery; and PRK/LASEK and ICRS implantation services. Its correction services are used for the treatment of myopia, high myopia, presbyopia, and cataract surgeries. The company serves mid-to-high income level customers, who primarily seek surgery to treat their myopia; and above 45 years of age, who primarily seek surgery to treat their presbyopia or cataract. It operates consultation centers and clinics for eye treatment and LASIK centers; and sells pharmaceutical products. The company is also involved in eye clinic equipment and lenses trading; and ophthalmic equipment renting and spaces operating activities. The company was founded in 1993 and is headquartered in Hamburg, Germany.",
        "currency": "HKD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "HKG",
        "market": "hk_market",
        "country": "Germany",
        "city": "Hamburg"
    },
    "22UA.F": {
        "short_name": "BIONTECH SE SPON. ADRS 1",
        "long_name": "BioNTech SE",
        "summary": "BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/II trial for prostate cancer; BNT113, which is in Phase I trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116, which is in preclinical trail for non-small cell lung cancer. It also develops neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I/II clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Eli Lilly and Company; Bayer AG; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc.; and InstaDeep Ltd. The company was founded in 2008 and is headquartered in Mainz, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Mainz"
    },
    "39K.F": {
        "short_name": "CENTOGENE N.V. EO -,12",
        "long_name": "Centogene N.V.",
        "summary": "Centogene N.V., together with its subsidiaries, engages in diagnosis and research around rare diseases that transform clinical and genetic data into information for patients, physicians, and pharmaceutical companies. Its platform analyzes epidemiologic, phenotypic, and genetic data to enhance the understanding of rare hereditary diseases. The company operates through two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Diagnostics segment provides genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Rostock"
    },
    "39K.MU": {
        "short_name": "CENTOGENE N.V. EO -,12",
        "long_name": "Centogene N.V.",
        "summary": "Centogene N.V., together with its subsidiaries, engages in diagnosis and research around rare diseases that transform clinical and genetic data into information for patients, physicians, and pharmaceutical companies. Its platform analyzes epidemiologic, phenotypic, and genetic data to enhance the understanding of rare hereditary diseases. The company operates through two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Diagnostics segment provides genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "Germany",
        "city": "Rostock"
    },
    "5CV.F": {
        "short_name": "CUREVAC N.V.  O.N.",
        "long_name": "CureVac N.V.",
        "summary": "CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). Its lead proprietary programs include CV8102 that is in a Phase 1 dose escalating clinical trials for four types of cancers as a monotherapy and in combination with anti-PD-1; and CV7202, which is in a Phase 1 clinical trials as a vaccine candidate against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase 1 clinical trial. The company's partnered programs comprise BI1361849, a therapeutic vaccine candidate that is in a Phase 1/2 clinical trials to elicit antigen-specific immune responses against tumor-associated antigens frequently overexpressed in patients with non-small cell lung cancer; Cas9 mRNA constructs for use in gene editing therapeutics; mRNA based novel therapeutic antibodies; prophylactic vaccines to prevent picornaviruses, influenza, malaria, and rotavirus; and programs against SARS-CoV-2, Lassa virus, and yellow fever. It has strategic partnerships with Genmab, Arcturus, Acuitas, CRISPR Therapeutics, Boehringer Ingelheim, GlaxoSmithKline, the Bill & Melinda Gates Foundation, CEPI, Tesla Grohmann, and others. The company was founded in 2000 and is headquartered in T\u00c3\u00bcbingen, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "T\u00c3\u00bcbingen"
    },
    "A28.F": {
        "short_name": "AFFIMED N.V.  EO-,01",
        "long_name": "Affimed N.V.",
        "summary": "Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which has completed Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager for the treatment of advanced cancer patients; AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific antibodies for the treatment of multiple myeloma. In addition, it is developing AFM11, a T cell engager for the treatment of CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb that is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Corporation; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product; Genentech; and Roivant Sciences. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Heidelberg"
    },
    "AAQ1.DE": {
        "short_name": "AAP IMPLANTATE AG O.N.",
        "long_name": "aap Implantate AG",
        "summary": "aap Implantate AG, a medical device company, develops, manufactures, and markets trauma products for orthopedics in Germany, the United States, and internationally. It offers LOQTEQ, an anatomical plating system for fracture treatment; and a range of cannulated screws, standard plates, and screws. The company sells its products directly to hospitals, buying syndicates, and hospital groups, as well as through a network of distributors under the aap brand name. aap Implantate AG was founded in 1990 and is headquartered in Berlin, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Berlin"
    },
    "AAQ1.F": {
        "short_name": "AAP IMPLANTATE AG O.N.",
        "long_name": "aap Implantate AG",
        "summary": "aap Implantate AG, a medical device company, develops, manufactures, and markets trauma products for orthopedics in Germany, the United States, and internationally. It offers LOQTEQ, an anatomical plating system for fracture treatment; and a range of cannulated screws, standard plates, and screws. The company sells its products directly to hospitals, buying syndicates, and hospital groups, as well as through a network of distributors under the aap brand name. aap Implantate AG was founded in 1990 and is headquartered in Berlin, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Berlin"
    },
    "AFMD": {
        "short_name": "Affimed N.V.",
        "long_name": "Affimed N.V.",
        "summary": "Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which has completed Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager for the treatment of advanced cancer patients; AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific antibodies for the treatment of multiple myeloma. In addition, it is developing AFM11, a T cell engager for the treatment of CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb that is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Corporation; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product; Genentech; and Roivant Sciences. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "Germany",
        "city": "Heidelberg"
    },
    "AFX.DE": {
        "short_name": "CARL ZEISS MEDITEC AG",
        "long_name": "Carl Zeiss Meditec AG",
        "summary": "Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, other Europe countries, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery. This segment also offers optical coherence tomography devices, perimeters, fundus cameras, slit lamps, and therapeutic and refractive lasers for the diagnosis and treatment of various eye diseases, such as refraction, glaucoma, and other retinal diseases, as well as FORUM, an eye care data management system. The Microsurgery segment provides surgical microscopes and visualization solutions for neuro, spinal, dental, and plastic and reconstructive surgeries, as well as for ear, nose, and throat surgery; products for surgical treatment of tumors or vascular diseases, such as aneurysms; and INTRABEAM, a intraoperative radiotherapy device. Carl Zeiss Meditec AG serves ophthalmologists and optometrists, as well as physicians and surgeons in hospitals and outpatient surgery centers. The company was founded in 2002 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Jena"
    },
    "AFX.F": {
        "short_name": "CARL ZEISS MEDITEC AG",
        "long_name": "Carl Zeiss Meditec AG",
        "summary": "Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, other Europe countries, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery. This segment also offers optical coherence tomography devices, perimeters, fundus cameras, slit lamps, and therapeutic and refractive lasers for the diagnosis and treatment of various eye diseases, such as refraction, glaucoma, and other retinal diseases, as well as FORUM, an eye care data management system. The Microsurgery segment provides surgical microscopes and visualization solutions for neuro, spinal, dental, and plastic and reconstructive surgeries, as well as for ear, nose, and throat surgery; products for surgical treatment of tumors or vascular diseases, such as aneurysms; and INTRABEAM, a intraoperative radiotherapy device. Carl Zeiss Meditec AG serves ophthalmologists and optometrists, as well as physicians and surgeons in hospitals and outpatient surgery centers. The company was founded in 2002 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Jena"
    },
    "AFX.VI": {
        "short_name": "CARL ZEISS MEDITEC AG",
        "long_name": "Carl Zeiss Meditec AG",
        "summary": "Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, other Europe countries, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery. This segment also offers optical coherence tomography devices, perimeters, fundus cameras, slit lamps, and therapeutic and refractive lasers for the diagnosis and treatment of various eye diseases, such as refraction, glaucoma, and other retinal diseases, as well as FORUM, an eye care data management system. The Microsurgery segment provides surgical microscopes and visualization solutions for neuro, spinal, dental, and plastic and reconstructive surgeries, as well as for ear, nose, and throat surgery; products for surgical treatment of tumors or vascular diseases, such as aneurysms; and INTRABEAM, a intraoperative radiotherapy device. Carl Zeiss Meditec AG serves ophthalmologists and optometrists, as well as physicians and surgeons in hospitals and outpatient surgery centers. The company was founded in 2002 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Germany",
        "city": "Jena"
    },
    "AFXA.F": {
        "short_name": "CARL ZEISS MEDITEC ADR 1",
        "long_name": "Carl Zeiss Meditec AG",
        "summary": "Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, other Europe countries, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery. This segment also offers optical coherence tomography devices, perimeters, fundus cameras, slit lamps, and therapeutic and refractive lasers for the diagnosis and treatment of various eye diseases, such as refraction, glaucoma, and other retinal diseases, as well as FORUM, an eye care data management system. The Microsurgery segment provides surgical microscopes and visualization solutions for neuro, spinal, dental, and plastic and reconstructive surgeries, as well as for ear, nose, and throat surgery; products for surgical treatment of tumors or vascular diseases, such as aneurysms; and INTRABEAM, a intraoperative radiotherapy device. Carl Zeiss Meditec AG serves ophthalmologists and optometrists, as well as physicians and surgeons in hospitals and outpatient surgery centers. The company was founded in 2002 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Jena"
    },
    "AJ91.DE": {
        "short_name": "DOCCHECK AG NA O.N.",
        "long_name": "DocCheck AG",
        "summary": "DocCheck AG provides marketing, customer relationship management, and e-commerce services for the healthcare sector in Europe. The company operates DocCheck portal for exchanging information on the Internet, and online and e-commerce services for healthcare market players. It also develops and implements communication strategies for new and traditional media on healthcare and business-to-business sectors; and promotes healthcare startups through seed funding. DocCheck AG is based in Cologne, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Cologne"
    },
    "AJ91.F": {
        "short_name": "DOCCHECK AG NA O.N.",
        "long_name": "DocCheck AG",
        "summary": "DocCheck AG provides marketing, customer relationship management, and e-commerce services for the healthcare sector in Europe. The company operates DocCheck portal for exchanging information on the Internet, and online and e-commerce services for healthcare market players. It also develops and implements communication strategies for new and traditional media on healthcare and business-to-business sectors; and promotes healthcare startups through seed funding. DocCheck AG is based in Cologne, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Cologne"
    },
    "ALNOX.PA": {
        "short_name": "NOXXON",
        "long_name": "NOXXON Pharma N.V.",
        "summary": "NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. The company is also developing NOX-E36, which has completed Phase IIa clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "Germany",
        "city": "Berlin"
    },
    "B8F.DE": {
        "short_name": "BIOFRONTERA AG NA O.N.",
        "long_name": "Biofrontera AG",
        "summary": "Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Leverkusen"
    },
    "B8F.F": {
        "short_name": "BIOFRONTERA AG NA O.N.",
        "long_name": "Biofrontera AG",
        "summary": "Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Leverkusen"
    },
    "B8FE.SG": {
        "short_name": "Biofrontera AG (Spons.ADRs)/2 o",
        "long_name": "Biofrontera AG",
        "summary": "Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "Germany",
        "city": "Leverkusen"
    },
    "BAYA.DE": {
        "short_name": "BAYER ADR /1/4",
        "long_name": "Bayer Aktiengesellschaft",
        "summary": "Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, and self-care solutions in the dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center at the University of Texas to develop cancer treatments; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies, supermarket and drugstore chains, online and other retailers, and hospitals, as well as directly to farmers. It has strategic research alliance with Kyoto University, Sensyne Health plc, and Atomwise Inc. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Leverkusen"
    },
    "BAYA.F": {
        "short_name": "BAYER ADR /1/4",
        "long_name": "Bayer Aktiengesellschaft",
        "summary": "Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, and self-care solutions in the dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center at the University of Texas to develop cancer treatments; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies, supermarket and drugstore chains, online and other retailers, and hospitals, as well as directly to farmers. It has strategic research alliance with Kyoto University, Sensyne Health plc, and Atomwise Inc. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Leverkusen"
    },
    "BAYN.DE": {
        "short_name": "BAYER AG NA O.N.",
        "long_name": "Bayer Aktiengesellschaft",
        "summary": "Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, and self-care solutions in the dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center at the University of Texas to develop cancer treatments; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies, supermarket and drugstore chains, online and other retailers, and hospitals, as well as directly to farmers. It has strategic research alliance with Kyoto University, Sensyne Health plc, and Atomwise Inc. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Leverkusen"
    },
    "BAYN.F": {
        "short_name": "BAYER AG NA O.N.",
        "long_name": "Bayer Aktiengesellschaft",
        "summary": "Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, and self-care solutions in the dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center at the University of Texas to develop cancer treatments; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies, supermarket and drugstore chains, online and other retailers, and hospitals, as well as directly to farmers. It has strategic research alliance with Kyoto University, Sensyne Health plc, and Atomwise Inc. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Leverkusen"
    },
    "BAYN.VI": {
        "short_name": "BAYER AG",
        "long_name": "Bayer Aktiengesellschaft",
        "summary": "Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, and self-care solutions in the dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center at the University of Texas to develop cancer treatments; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies, supermarket and drugstore chains, online and other retailers, and hospitals, as well as directly to farmers. It has strategic research alliance with Kyoto University, Sensyne Health plc, and Atomwise Inc. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Germany",
        "city": "Leverkusen"
    },
    "BAYNN.MX": {
        "short_name": "BAYER AG",
        "long_name": "Bayer Aktiengesellschaft",
        "summary": "Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, and self-care solutions in the dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center at the University of Texas to develop cancer treatments; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies, supermarket and drugstore chains, online and other retailers, and hospitals, as well as directly to farmers. It has strategic research alliance with Kyoto University, Sensyne Health plc, and Atomwise Inc. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Major",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "Germany",
        "city": "Leverkusen"
    },
    "BAYRY": {
        "short_name": "BAYER AG",
        "long_name": "Bayer Aktiengesellschaft",
        "summary": "Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, and self-care solutions in the dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center at the University of Texas to develop cancer treatments; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies, supermarket and drugstore chains, online and other retailers, and hospitals, as well as directly to farmers. It has strategic research alliance with Kyoto University, Sensyne Health plc, and Atomwise Inc. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Leverkusen"
    },
    "BAYZF": {
        "short_name": "BAYER AG",
        "long_name": "Bayer Aktiengesellschaft",
        "summary": "Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, and self-care solutions in the dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center at the University of Texas to develop cancer treatments; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies, supermarket and drugstore chains, online and other retailers, and hospitals, as well as directly to farmers. It has strategic research alliance with Kyoto University, Sensyne Health plc, and Atomwise Inc. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Leverkusen"
    },
    "BFRA": {
        "short_name": "Biofrontera AG American Deposit",
        "long_name": "Biofrontera AG",
        "summary": "Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Germany",
        "city": "Leverkusen"
    },
    "BNN.DE": {
        "short_name": "B.R.A.I.N. NA",
        "long_name": "B.R.A.I.N. Biotechnology Research and Information Network AG",
        "summary": "B.R.A.I.N. Biotechnology Research and Information Network AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical and consumer goods industries in Germany, the United States, France, and the United Kingdom. The company operates through BioScience and BioIndustrial segments. It identifies and develops bioactive natural compounds, including sugar substitutes and taste modulators, and natural-source substances for product development in the food, animal feed, skin care, cosmetics, and chemical industries. The company also identifies and develops optimized enzymes and biocatalysts for the production of food and beverages, and wound care preparations or lubricants, as well as for starch processing of bioethanol production; and microorganisms as the functional biomass for optimized industrial production processes, recycling of greenhouse gas CO2 as an industrial raw material, and extraction of precious and rare earth metals. It has strategic partnerships with AnalytiCon Discovery GmbH and Roquette to develop natural sweeteners and sweet taste enhancers. The company was founded in 1993 and is headquartered in Zwingenberg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Zwingenberg"
    },
    "BNN.F": {
        "short_name": "B.R.A.I.N. NA",
        "long_name": "B.R.A.I.N. Biotechnology Research and Information Network AG",
        "summary": "B.R.A.I.N. Biotechnology Research and Information Network AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical and consumer goods industries in Germany, the United States, France, and the United Kingdom. The company operates through BioScience and BioIndustrial segments. It identifies and develops bioactive natural compounds, including sugar substitutes and taste modulators, and natural-source substances for product development in the food, animal feed, skin care, cosmetics, and chemical industries. The company also identifies and develops optimized enzymes and biocatalysts for the production of food and beverages, and wound care preparations or lubricants, as well as for starch processing of bioethanol production; and microorganisms as the functional biomass for optimized industrial production processes, recycling of greenhouse gas CO2 as an industrial raw material, and extraction of precious and rare earth metals. It has strategic partnerships with AnalytiCon Discovery GmbH and Roquette to develop natural sweeteners and sweet taste enhancers. The company was founded in 1993 and is headquartered in Zwingenberg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Zwingenberg"
    },
    "BNTX": {
        "short_name": "BioNTech SE",
        "long_name": "BioNTech SE",
        "summary": "BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/II trial for prostate cancer; BNT113, which is in Phase I trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116, which is in preclinical trail for non-small cell lung cancer. It also develops neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I/II clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Eli Lilly and Company; Bayer AG; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc.; and InstaDeep Ltd. The company was founded in 2008 and is headquartered in Mainz, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Germany",
        "city": "Mainz"
    },
    "BNTX.VI": {
        "short_name": "BIONTECH SE ADR",
        "long_name": "BioNTech SE",
        "summary": "BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/II trial for prostate cancer; BNT113, which is in Phase I trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116, which is in preclinical trail for non-small cell lung cancer. It also develops neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I/II clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Eli Lilly and Company; Bayer AG; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc.; and InstaDeep Ltd. The company was founded in 2008 and is headquartered in Mainz, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Germany",
        "city": "Mainz"
    },
    "CAKFY": {
        "short_name": "MCKESSON EUROPE AG",
        "long_name": "McKesson Europe AG",
        "summary": "McKesson Europe AG provides logistics and services to the pharmaceutical and healthcare sectors worldwide. The company operates through two divisions, Consumer Solutions and Pharmacy Solutions. The Consumer Solutions division operates approximately 2,300 own and 300 managed retail pharmacies and approximately 7,000 participants in its brand partnership schemes. The Pharmacy Solutions division engages in the wholesale of pharmaceutical products. It also provides supplementary services for pharmacists, such as the organization and management of pharmacy cooperation programs in the United Kingdom, Germany, France, Portugal, and Belgium. This division serves its customers through 118 wholesale branches that supply approximately 100,000 pharmaceutical products to approximately 50,000 pharmacies and hospitals. The company was formerly known as Celesio AG and changed its name to McKesson Europe AG in September 2017. The company was founded in 1835 and is headquartered in Stuttgart, Germany. McKesson Europe AG operates as a subsidiary of McKesson Corporation.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Stuttgart"
    },
    "CDZ.MU": {
        "short_name": "LIFESPOT CAPITAL AG O.N.",
        "long_name": "Lifespot Capital AG",
        "summary": "Lifespot Capital AG offers telemedical and medical big data solutions to e-health market participants and stakeholders. Lifespot Capital AG was formerly known as NBIC Capital AG and changed its name to Lifespot Capital AG in May, 2015. The company was founded in 2005 and is based in Munich, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "Germany",
        "city": "Munich"
    },
    "CLS1.HM": {
        "short_name": "MCKESSON EUROPE  NA O.N.",
        "long_name": "McKesson Europe AG",
        "summary": "McKesson Europe AG provides logistics and services to the pharmaceutical and healthcare sectors worldwide. The company operates through two divisions, Consumer Solutions and Pharmacy Solutions. The Consumer Solutions division operates approximately 2,300 own and 300 managed retail pharmacies and approximately 7,000 participants in its brand partnership schemes. The Pharmacy Solutions division engages in the wholesale of pharmaceutical products. It also provides supplementary services for pharmacists, such as the organization and management of pharmacy cooperation programs in the United Kingdom, Germany, France, Portugal, and Belgium. This division serves its customers through 118 wholesale branches that supply approximately 100,000 pharmaceutical products to approximately 50,000 pharmacies and hospitals. The company was formerly known as Celesio AG and changed its name to McKesson Europe AG in September 2017. The company was founded in 1835 and is headquartered in Stuttgart, Germany. McKesson Europe AG operates as a subsidiary of McKesson Corporation.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "HAM",
        "market": "dr_market",
        "country": "Germany",
        "city": "Stuttgart"
    },
    "CMPVF": {
        "short_name": "COMPUGROUP MEDICAL SE & CO. KGA",
        "long_name": "Compugroup Medical SE & Co. KGaA",
        "summary": "Compugroup Medical SE & Co. KGaA develops and sells software and information technology services for the healthcare sector worldwide. It operates in four segments: Ambulatory Information Systems (AIS), Pharmacy Information Systems (PCS), Hospital Information Systems (HIS), and Consumer & Health Management Information Systems (CHS). The AIS segment provides practice management software and electronic medical records for doctors in private practice, medical care centers, and doctor's networks, as well as offers supplementary Internet and intranet solutions. The PCS segment provides integrated clinical, administrative, and billing-related software applications for pharmacies, as well as in-store and online merchandising programs supported by paper-based and electronic communication and advertising solutions. The HIS segment provides clinical and administrative solutions for the inpatient sector. This segment serves acute care hospitals; rehabilitation centers; and social services, including multi-location hospital networks and regional care organizations. The CHS segment provides communication and data solutions that allow pharmaceutical companies to provide information to healthcare providers through software interfaces. This segment offers clinical decision support systems, and medications and therapy databases for healthcare providers; and personal health records, consumer portals, and mobile applications solutions for healthcare IT companies, as well as collects and transfers anonymous clinical data for market studies, clinical trials, etc. It serves pharmaceutical companies, health insurance companies, and other healthcare IT companies and consumers. The company was formerly known as CompuGroup Medical SE and changed its name to Compugroup Medical SE & Co. KGaA in June 2020. Compugroup Medical SE & Co. KGaA is headquartered in Koblenz, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Koblenz"
    },
    "CNTG": {
        "short_name": "Centogene N.V.",
        "long_name": "Centogene N.V.",
        "summary": "Centogene N.V., together with its subsidiaries, engages in diagnosis and research around rare diseases that transform clinical and genetic data into information for patients, physicians, and pharmaceutical companies. Its platform analyzes epidemiologic, phenotypic, and genetic data to enhance the understanding of rare hereditary diseases. The company operates through two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Diagnostics segment provides genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NGM",
        "market": "us_market",
        "country": "Germany",
        "city": "Rostock"
    },
    "CNWK.DE": {
        "short_name": "CO.DON AG  INH. O.N.",
        "long_name": "co.don AG",
        "summary": "co.don AG engages in cell cultivation for the regenerative treatment of articular cartilage and spinal disc defects worldwide. The company develops, produces, and markets autologous cell therapies for the minimally invasive repair of cartilage damage to knee joints following traumatic or degenerative defects. Its therapies include matrix-associated autologous cartilage transplantation, a biological therapy for the treatment of damaged articular cartilage with the body's own cells; and autologous chondrocyte transplantation for the regeneration of biomechanical load-bearing and pressure-resistant cartilage tissue. co.don AG was founded in 1993 and is headquartered in Teltow, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Teltow"
    },
    "CNWK.F": {
        "short_name": "CO.DON AG  INH. O.N.",
        "long_name": "co.don AG",
        "summary": "co.don AG engages in cell cultivation for the regenerative treatment of articular cartilage and spinal disc defects worldwide. The company develops, produces, and markets autologous cell therapies for the minimally invasive repair of cartilage damage to knee joints following traumatic or degenerative defects. Its therapies include matrix-associated autologous cartilage transplantation, a biological therapy for the treatment of damaged articular cartilage with the body's own cells; and autologous chondrocyte transplantation for the regeneration of biomechanical load-bearing and pressure-resistant cartilage tissue. co.don AG was founded in 1993 and is headquartered in Teltow, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Teltow"
    },
    "COP.DE": {
        "short_name": "COMPUGROUP MED. NA O.N.",
        "long_name": "Compugroup Medical SE & Co. KGaA",
        "summary": "Compugroup Medical SE & Co. KGaA develops and sells software and information technology services for the healthcare sector worldwide. It operates in four segments: Ambulatory Information Systems (AIS), Pharmacy Information Systems (PCS), Hospital Information Systems (HIS), and Consumer & Health Management Information Systems (CHS). The AIS segment provides practice management software and electronic medical records for doctors in private practice, medical care centers, and doctor's networks, as well as offers supplementary Internet and intranet solutions. The PCS segment provides integrated clinical, administrative, and billing-related software applications for pharmacies, as well as in-store and online merchandising programs supported by paper-based and electronic communication and advertising solutions. The HIS segment provides clinical and administrative solutions for the inpatient sector. This segment serves acute care hospitals; rehabilitation centers; and social services, including multi-location hospital networks and regional care organizations. The CHS segment provides communication and data solutions that allow pharmaceutical companies to provide information to healthcare providers through software interfaces. This segment offers clinical decision support systems, and medications and therapy databases for healthcare providers; and personal health records, consumer portals, and mobile applications solutions for healthcare IT companies, as well as collects and transfers anonymous clinical data for market studies, clinical trials, etc. It serves pharmaceutical companies, health insurance companies, and other healthcare IT companies and consumers. The company was formerly known as CompuGroup Medical SE and changed its name to Compugroup Medical SE & Co. KGaA in June 2020. Compugroup Medical SE & Co. KGaA is headquartered in Koblenz, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Koblenz"
    },
    "CVAC": {
        "short_name": "CureVac N.V.",
        "long_name": "CureVac N.V.",
        "summary": "CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). Its lead proprietary programs include CV8102 that is in a Phase 1 dose escalating clinical trials for four types of cancers as a monotherapy and in combination with anti-PD-1; and CV7202, which is in a Phase 1 clinical trials as a vaccine candidate against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase 1 clinical trial. The company's partnered programs comprise BI1361849, a therapeutic vaccine candidate that is in a Phase 1/2 clinical trials to elicit antigen-specific immune responses against tumor-associated antigens frequently overexpressed in patients with non-small cell lung cancer; Cas9 mRNA constructs for use in gene editing therapeutics; mRNA based novel therapeutic antibodies; prophylactic vaccines to prevent picornaviruses, influenza, malaria, and rotavirus; and programs against SARS-CoV-2, Lassa virus, and yellow fever. It has strategic partnerships with Genmab, Arcturus, Acuitas, CRISPR Therapeutics, Boehringer Ingelheim, GlaxoSmithKline, the Bill & Melinda Gates Foundation, CEPI, Tesla Grohmann, and others. The company was founded in 2000 and is headquartered in T\u00c3\u00bcbingen, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Germany",
        "city": "T\u00c3\u00bcbingen"
    },
    "CVAC.VI": {
        "short_name": "CUREVAC NV",
        "long_name": "CureVac N.V.",
        "summary": "CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). Its lead proprietary programs include CV8102 that is in a Phase 1 dose escalating clinical trials for four types of cancers as a monotherapy and in combination with anti-PD-1; and CV7202, which is in a Phase 1 clinical trials as a vaccine candidate against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase 1 clinical trial. The company's partnered programs comprise BI1361849, a therapeutic vaccine candidate that is in a Phase 1/2 clinical trials to elicit antigen-specific immune responses against tumor-associated antigens frequently overexpressed in patients with non-small cell lung cancer; Cas9 mRNA constructs for use in gene editing therapeutics; mRNA based novel therapeutic antibodies; prophylactic vaccines to prevent picornaviruses, influenza, malaria, and rotavirus; and programs against SARS-CoV-2, Lassa virus, and yellow fever. It has strategic partnerships with Genmab, Arcturus, Acuitas, CRISPR Therapeutics, Boehringer Ingelheim, GlaxoSmithKline, the Bill & Melinda Gates Foundation, CEPI, Tesla Grohmann, and others. The company was founded in 2000 and is headquartered in T\u00c3\u00bcbingen, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Germany",
        "city": "T\u00c3\u00bcbingen"
    },
    "CZMWF": {
        "short_name": "CARL ZEISS MEDITEC AG",
        "long_name": "Carl Zeiss Meditec AG",
        "summary": "Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, other Europe countries, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery. This segment also offers optical coherence tomography devices, perimeters, fundus cameras, slit lamps, and therapeutic and refractive lasers for the diagnosis and treatment of various eye diseases, such as refraction, glaucoma, and other retinal diseases, as well as FORUM, an eye care data management system. The Microsurgery segment provides surgical microscopes and visualization solutions for neuro, spinal, dental, and plastic and reconstructive surgeries, as well as for ear, nose, and throat surgery; products for surgical treatment of tumors or vascular diseases, such as aneurysms; and INTRABEAM, a intraoperative radiotherapy device. Carl Zeiss Meditec AG serves ophthalmologists and optometrists, as well as physicians and surgeons in hospitals and outpatient surgery centers. The company was founded in 2002 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Jena"
    },
    "CZMWY": {
        "short_name": "CARL ZEISS MEDITEC AG",
        "long_name": "Carl Zeiss Meditec AG",
        "summary": "Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, other Europe countries, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery. This segment also offers optical coherence tomography devices, perimeters, fundus cameras, slit lamps, and therapeutic and refractive lasers for the diagnosis and treatment of various eye diseases, such as refraction, glaucoma, and other retinal diseases, as well as FORUM, an eye care data management system. The Microsurgery segment provides surgical microscopes and visualization solutions for neuro, spinal, dental, and plastic and reconstructive surgeries, as well as for ear, nose, and throat surgery; products for surgical treatment of tumors or vascular diseases, such as aneurysms; and INTRABEAM, a intraoperative radiotherapy device. Carl Zeiss Meditec AG serves ophthalmologists and optometrists, as well as physicians and surgeons in hospitals and outpatient surgery centers. The company was founded in 2002 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Jena"
    },
    "DGWPF": {
        "short_name": "DRAEGERWERK AG & CO KGAA",
        "long_name": "Dr\u00e4gerwerk AG & Co. KGaA",
        "summary": "Dr\u00c3\u00a4gerwerk AG & Co. KGaA operates as medical and safety technology company in Europe, the Americas, Africa, Asia, and Australia. The company develops, produces, and markets system solutions, equipment, and services for acute point of care, including emergency care, perioperative care, critical care, and perinatal care. It also develops, produces, and markets products, system solutions, and services for personal protection, gas detection technology, and integrated hazard management to customers in industry and mining sectors, as well as public sectors, such as fire departments, police, and disaster protection. The company's products portfolio includes anesthesia devices and ventilators, thermoregulation equipment, generic and device-specific consumables and accessories, supply units, lights, gas management systems, patient monitoring, software applications, and system products. Its product portfolio also comprises stationary and mobile gas detection systems, personal protective equipment, professional diving systems, and alcohol and drug testing devices. In addition, the company offers various training and services, as well as undertakes projects that include fire training systems and interchangeable special units for tunnel rescue trains. Dr\u00c3\u00a4gerwerk AG & Co. KGaA was founded in 1889 and is headquartered in L\u00c3\u00bcbeck, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "L\u00c3\u00bcbeck"
    },
    "DMP.DE": {
        "short_name": "DERMAPHARM HLDG INH O.N.",
        "long_name": "Dermapharm Holding SE",
        "summary": "Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Herbal Extracts, and Parallel Import Business. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, cosmetics, and dietary and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, enzymes, dermatologics, systemic corticoids, women's healthcare, pain treatment, and ophthalmologics under the Dekristol, Ampho-Moronal, and Prednisolut brands. In addition, the company provides hyperthermic medical devices under the bite away and Herpotherm names; food supplements under the H\u00c3\u00bcbner brand; and Azedil, a nasal spray and eye drop product to treat acute hay fever symptoms. Further, it engages in the parallel import pharmaceutical business under the axicorp brand. Additionally, the company offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetic products under the ABAlife, Mediteanox, and Pomanox names. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in Gr\u00c3\u00bcnwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Gr\u00c3\u00bcnwald"
    },
    "DMP.F": {
        "short_name": "DERMAPHARM HLDG INH O.N.",
        "long_name": "Dermapharm Holding SE",
        "summary": "Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Herbal Extracts, and Parallel Import Business. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, cosmetics, and dietary and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, enzymes, dermatologics, systemic corticoids, women's healthcare, pain treatment, and ophthalmologics under the Dekristol, Ampho-Moronal, and Prednisolut brands. In addition, the company provides hyperthermic medical devices under the bite away and Herpotherm names; food supplements under the H\u00c3\u00bcbner brand; and Azedil, a nasal spray and eye drop product to treat acute hay fever symptoms. Further, it engages in the parallel import pharmaceutical business under the axicorp brand. Additionally, the company offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetic products under the ABAlife, Mediteanox, and Pomanox names. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in Gr\u00c3\u00bcnwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Gr\u00c3\u00bcnwald"
    },
    "DRW3.DE": {
        "short_name": "DRAEGERWERK VZO O.N.",
        "long_name": "Dr\u00e4gerwerk AG & Co. KGaA",
        "summary": "Dr\u00c3\u00a4gerwerk AG & Co. KGaA operates as medical and safety technology company in Europe, the Americas, Africa, Asia, and Australia. The company develops, produces, and markets system solutions, equipment, and services for acute point of care, including emergency care, perioperative care, critical care, and perinatal care. It also develops, produces, and markets products, system solutions, and services for personal protection, gas detection technology, and integrated hazard management to customers in industry and mining sectors, as well as public sectors, such as fire departments, police, and disaster protection. The company's products portfolio includes anesthesia devices and ventilators, thermoregulation equipment, generic and device-specific consumables and accessories, supply units, lights, gas management systems, patient monitoring, software applications, and system products. Its product portfolio also comprises stationary and mobile gas detection systems, personal protective equipment, professional diving systems, and alcohol and drug testing devices. In addition, the company offers various training and services, as well as undertakes projects that include fire training systems and interchangeable special units for tunnel rescue trains. Dr\u00c3\u00a4gerwerk AG & Co. KGaA was founded in 1889 and is headquartered in L\u00c3\u00bcbeck, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "L\u00c3\u00bcbeck"
    },
    "DRW8.DE": {
        "short_name": "DRAEGERWERK ST.A.O.N.",
        "long_name": "Dr\u00e4gerwerk AG & Co. KGaA",
        "summary": "Dr\u00c3\u00a4gerwerk AG & Co. KGaA operates as medical and safety technology company in Europe, the Americas, Africa, Asia, and Australia. The company develops, produces, and markets system solutions, equipment, and services for acute point of care, including emergency care, perioperative care, critical care, and perinatal care. It also develops, produces, and markets products, system solutions, and services for personal protection, gas detection technology, and integrated hazard management to customers in industry and mining sectors, as well as public sectors, such as fire departments, police, and disaster protection. The company's products portfolio includes anesthesia devices and ventilators, thermoregulation equipment, generic and device-specific consumables and accessories, supply units, lights, gas management systems, patient monitoring, software applications, and system products. Its product portfolio also comprises stationary and mobile gas detection systems, personal protective equipment, professional diving systems, and alcohol and drug testing devices. In addition, the company offers various training and services, as well as undertakes projects that include fire training systems and interchangeable special units for tunnel rescue trains. Dr\u00c3\u00a4gerwerk AG & Co. KGaA was founded in 1889 and is headquartered in L\u00c3\u00bcbeck, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "L\u00c3\u00bcbeck"
    },
    "E8X.DE": {
        "short_name": "ELEXXION AG",
        "long_name": "elexxion AG",
        "summary": "elexxion AG develops, produces, and sells dental lasers for soft and hard tissue applications primarily in Germany. It offers dental diode lasers under the elexxion pico, elexxion nano, and elexxion claros names; and elexxion pico lite, a soft laser therapy. The company also provides Odobleach, an in-office bleaching gel for treatment in a dental office; and perio green, a therapy product for the photothermal therapy of periodontology and periimplantitis, as well as offers repair services. It serves dental hygienists and assistants. The company was founded in 2002 and is headquartered in Singen, Germany. elexxion AG is a subsidiary of Tian Ying Medical Instrument Co., Ltd.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Singen"
    },
    "E8X.F": {
        "short_name": "ELEXXION AG",
        "long_name": "elexxion AG",
        "summary": "elexxion AG develops, produces, and sells dental lasers for soft and hard tissue applications primarily in Germany. It offers dental diode lasers under the elexxion pico, elexxion nano, and elexxion claros names; and elexxion pico lite, a soft laser therapy. The company also provides Odobleach, an in-office bleaching gel for treatment in a dental office; and perio green, a therapy product for the photothermal therapy of periodontology and periimplantitis, as well as offers repair services. It serves dental hygienists and assistants. The company was founded in 2002 and is headquartered in Singen, Germany. elexxion AG is a subsidiary of Tian Ying Medical Instrument Co., Ltd.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Singen"
    },
    "ECX.DE": {
        "short_name": "EPIGENOMICS AG NA O.N.",
        "long_name": "Epigenomics AG",
        "summary": "Epigenomics AG, a cancer molecular diagnostics company, develops and commercializes blood-based diagnostic tests across multiple cancer indications with high medical needs in Europe, North America, Asia, and internationally. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer using its proprietary DNA methylation biomarker, Septin9. The company also offers Hepatocellular carcinoma Blood Test, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma; Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its development pipeline also contains products for screening, early detection, and diagnosis of cancers. In addition, the company engages in the identification of biomarker opportunities for various cancers, such as bladder cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Berlin"
    },
    "EIF.F": {
        "short_name": "EIFELHOEHEN-KLINIK O.N.",
        "long_name": "Eifelh\u00f6hen-Klinik AG",
        "summary": "Eifelh\u00c3\u00b6hen-Klinik AG operates facilities for outpatient and inpatient rehabilitation, elderly care, and outpatient medical care in Germany. It operates clinics that provide rehabilitation services in the areas of geriatrics, internal medicine, orthopedics, neurology, cardiology, and neurosurgery, as well as stroke diseases. The company also operates a care facility with 39 beds and a medical care center. Eifelh\u00c3\u00b6hen-Klinik AG was founded in 1970 and is headquartered in Bonn, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Bonn"
    },
    "EPGND": {
        "short_name": "EPIGENOMICS AG",
        "long_name": "Epigenomics AG",
        "summary": "Epigenomics AG, a cancer molecular diagnostics company, develops and commercializes blood-based diagnostic tests across multiple cancer indications with high medical needs in Europe, North America, Asia, and internationally. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer using its proprietary DNA methylation biomarker, Septin9. The company also offers Hepatocellular carcinoma Blood Test, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma; Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its development pipeline also contains products for screening, early detection, and diagnosis of cancers. In addition, the company engages in the identification of biomarker opportunities for various cancers, such as bladder cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Berlin"
    },
    "EPGNF": {
        "short_name": "EPIGENOMICS AG",
        "long_name": "Epigenomics AG",
        "summary": "Epigenomics AG, a cancer molecular diagnostics company, develops and commercializes blood-based diagnostic tests across multiple cancer indications with high medical needs in Europe, North America, Asia, and internationally. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer using its proprietary DNA methylation biomarker, Septin9. The company also offers Hepatocellular carcinoma Blood Test, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma; Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its development pipeline also contains products for screening, early detection, and diagnosis of cancers. In addition, the company engages in the identification of biomarker opportunities for various cancers, such as bladder cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Berlin"
    },
    "EPGNY": {
        "short_name": "EPIGENOMICS AG",
        "long_name": "Epigenomics AG",
        "summary": "Epigenomics AG, a cancer molecular diagnostics company, develops and commercializes blood-based diagnostic tests across multiple cancer indications with high medical needs in Europe, North America, Asia, and internationally. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer using its proprietary DNA methylation biomarker, Septin9. The company also offers Hepatocellular carcinoma Blood Test, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma; Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its development pipeline also contains products for screening, early detection, and diagnosis of cancers. In addition, the company engages in the identification of biomarker opportunities for various cancers, such as bladder cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Berlin"
    },
    "EUZ.DE": {
        "short_name": "ECKERT+ZIEGLER AG O.N.",
        "long_name": "Eckert & Ziegler Strahlen- und Medizintechnik AG",
        "summary": "Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, provides isotope technology components for medical, scientific, and industrial use worldwide. It operates through three segments: Radiation Therapy, Radiopharma, and Isotope Products. The Radiation Therapy segment develops, manufactures, markets, and sells radioactive products for cancer therapy. This segment offers small radioactive implants for the treatment of prostate cancer seeds; and tumor radiation devices and eye applicators. This segment's products and equipment are used by oncologists, radiotherapists, urologists, ophthalmologists, and medical physicists. The Radiopharma segment operates in the field of molecular imaging and nuclear medicine; and supplies various radiopharmaceuticals, radiochemicals, and related equipment for the synthesis and radiochromatography of PET/SPECT tracers and other radioisotopes. This segment provides products in the categories of radiosynthesis technology, radiochromatography, and radionuclides. The Isotope Products segment offers sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration, and environmental monitoring sources and solutions; and bulk radioisotopes for pharmaceutical, therapeutic, and industrial product manufacturers. It also provides custom and one-off design and manufacturing services. In addition, the company offers services for collection, recycling, and disposal of sealed radioactive sources and low activity isotope related waste from hospitals, research institutes, and industries. Eckert & Ziegler Strahlen- und Medizintechnik AG was founded in 1992 and is headquartered in Berlin, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Berlin"
    },
    "EUZ.F": {
        "short_name": "ECKERT+ZIEGLER AG O.N.",
        "long_name": "Eckert & Ziegler Strahlen- und Medizintechnik AG",
        "summary": "Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, provides isotope technology components for medical, scientific, and industrial use worldwide. It operates through three segments: Radiation Therapy, Radiopharma, and Isotope Products. The Radiation Therapy segment develops, manufactures, markets, and sells radioactive products for cancer therapy. This segment offers small radioactive implants for the treatment of prostate cancer seeds; and tumor radiation devices and eye applicators. This segment's products and equipment are used by oncologists, radiotherapists, urologists, ophthalmologists, and medical physicists. The Radiopharma segment operates in the field of molecular imaging and nuclear medicine; and supplies various radiopharmaceuticals, radiochemicals, and related equipment for the synthesis and radiochromatography of PET/SPECT tracers and other radioisotopes. This segment provides products in the categories of radiosynthesis technology, radiochromatography, and radionuclides. The Isotope Products segment offers sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration, and environmental monitoring sources and solutions; and bulk radioisotopes for pharmaceutical, therapeutic, and industrial product manufacturers. It also provides custom and one-off design and manufacturing services. In addition, the company offers services for collection, recycling, and disposal of sealed radioactive sources and low activity isotope related waste from hospitals, research institutes, and industries. Eckert & Ziegler Strahlen- und Medizintechnik AG was founded in 1992 and is headquartered in Berlin, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Berlin"
    },
    "EVOTF": {
        "short_name": "EVOTEC SE",
        "long_name": "Evotec SE",
        "summary": "Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services. Its EVT Innovate segment is involved in investing and developing early-stage discovery programs, as well as advanced drug candidates in the areas of diabetes and diabetic complications, inflammatory diseases, neuroscience, oncology, and pain and anti-infective. Evotec SE has a strategic drug discovery and development partnership with Celgene Corporation; strategic research alliance with Novo Nordisk A/S and Celmatix Inc.; collaboration with Sanofi; research collaboration with Almirall; research alliance with Ferring Pharmaceuticals; strategic collaboration with Centogene; collaboration with Immuneering; drug discovery alliance with LEO Pharma; strategic partnerships with the Sensyne Health plc, Oxford University Innovation Ltd., Secarna Pharmaceuticals GmbH & Co. KG, and Oxford Sciences Innovation to fund LAB10x; and drug discovery and development partnership with Aeovian Pharmaceuticals Inc. The company also has a collaboration with Indivumed GmbH; a partnership with Celmatix Inc.; a strategic collaboration with Ildong Pharmaceutical Co., Ltd.; a drug discovery research collaboration with HitGen Inc.; a partnership with Rappta Therapeutics; and a partnership with Sartorius. The company was founded in 1993 and is headquartered in Hamburg, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Hamburg"
    },
    "EVT.DE": {
        "short_name": "EVOTEC SE  INH O.N.",
        "long_name": "Evotec SE",
        "summary": "Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services. Its EVT Innovate segment is involved in investing and developing early-stage discovery programs, as well as advanced drug candidates in the areas of diabetes and diabetic complications, inflammatory diseases, neuroscience, oncology, and pain and anti-infective. Evotec SE has a strategic drug discovery and development partnership with Celgene Corporation; strategic research alliance with Novo Nordisk A/S and Celmatix Inc.; collaboration with Sanofi; research collaboration with Almirall; research alliance with Ferring Pharmaceuticals; strategic collaboration with Centogene; collaboration with Immuneering; drug discovery alliance with LEO Pharma; strategic partnerships with the Sensyne Health plc, Oxford University Innovation Ltd., Secarna Pharmaceuticals GmbH & Co. KG, and Oxford Sciences Innovation to fund LAB10x; and drug discovery and development partnership with Aeovian Pharmaceuticals Inc. The company also has a collaboration with Indivumed GmbH; a partnership with Celmatix Inc.; a strategic collaboration with Ildong Pharmaceutical Co., Ltd.; a drug discovery research collaboration with HitGen Inc.; a partnership with Rappta Therapeutics; and a partnership with Sartorius. The company was founded in 1993 and is headquartered in Hamburg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Hamburg"
    },
    "EVT.F": {
        "short_name": "EVOTEC SE  INH O.N.",
        "long_name": "Evotec SE",
        "summary": "Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services. Its EVT Innovate segment is involved in investing and developing early-stage discovery programs, as well as advanced drug candidates in the areas of diabetes and diabetic complications, inflammatory diseases, neuroscience, oncology, and pain and anti-infective. Evotec SE has a strategic drug discovery and development partnership with Celgene Corporation; strategic research alliance with Novo Nordisk A/S and Celmatix Inc.; collaboration with Sanofi; research collaboration with Almirall; research alliance with Ferring Pharmaceuticals; strategic collaboration with Centogene; collaboration with Immuneering; drug discovery alliance with LEO Pharma; strategic partnerships with the Sensyne Health plc, Oxford University Innovation Ltd., Secarna Pharmaceuticals GmbH & Co. KG, and Oxford Sciences Innovation to fund LAB10x; and drug discovery and development partnership with Aeovian Pharmaceuticals Inc. The company also has a collaboration with Indivumed GmbH; a partnership with Celmatix Inc.; a strategic collaboration with Ildong Pharmaceutical Co., Ltd.; a drug discovery research collaboration with HitGen Inc.; a partnership with Rappta Therapeutics; and a partnership with Sartorius. The company was founded in 1993 and is headquartered in Hamburg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Hamburg"
    },
    "EVTA.DE": {
        "short_name": "EVOTEC SE ADR/2 O.N.",
        "long_name": "Evotec SE",
        "summary": "Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services. Its EVT Innovate segment is involved in investing and developing early-stage discovery programs, as well as advanced drug candidates in the areas of diabetes and diabetic complications, inflammatory diseases, neuroscience, oncology, and pain and anti-infective. Evotec SE has a strategic drug discovery and development partnership with Celgene Corporation; strategic research alliance with Novo Nordisk A/S and Celmatix Inc.; collaboration with Sanofi; research collaboration with Almirall; research alliance with Ferring Pharmaceuticals; strategic collaboration with Centogene; collaboration with Immuneering; drug discovery alliance with LEO Pharma; strategic partnerships with the Sensyne Health plc, Oxford University Innovation Ltd., Secarna Pharmaceuticals GmbH & Co. KG, and Oxford Sciences Innovation to fund LAB10x; and drug discovery and development partnership with Aeovian Pharmaceuticals Inc. The company also has a collaboration with Indivumed GmbH; a partnership with Celmatix Inc.; a strategic collaboration with Ildong Pharmaceutical Co., Ltd.; a drug discovery research collaboration with HitGen Inc.; a partnership with Rappta Therapeutics; and a partnership with Sartorius. The company was founded in 1993 and is headquartered in Hamburg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Hamburg"
    },
    "EVTA.F": {
        "short_name": "EVOTEC SE ADR/2 O.N.",
        "long_name": "Evotec SE",
        "summary": "Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services. Its EVT Innovate segment is involved in investing and developing early-stage discovery programs, as well as advanced drug candidates in the areas of diabetes and diabetic complications, inflammatory diseases, neuroscience, oncology, and pain and anti-infective. Evotec SE has a strategic drug discovery and development partnership with Celgene Corporation; strategic research alliance with Novo Nordisk A/S and Celmatix Inc.; collaboration with Sanofi; research collaboration with Almirall; research alliance with Ferring Pharmaceuticals; strategic collaboration with Centogene; collaboration with Immuneering; drug discovery alliance with LEO Pharma; strategic partnerships with the Sensyne Health plc, Oxford University Innovation Ltd., Secarna Pharmaceuticals GmbH & Co. KG, and Oxford Sciences Innovation to fund LAB10x; and drug discovery and development partnership with Aeovian Pharmaceuticals Inc. The company also has a collaboration with Indivumed GmbH; a partnership with Celmatix Inc.; a strategic collaboration with Ildong Pharmaceutical Co., Ltd.; a drug discovery research collaboration with HitGen Inc.; a partnership with Rappta Therapeutics; and a partnership with Sartorius. The company was founded in 1993 and is headquartered in Hamburg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Hamburg"
    },
    "EVTCY": {
        "short_name": "EVOTEC SE",
        "long_name": "Evotec SE",
        "summary": "Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services. Its EVT Innovate segment is involved in investing and developing early-stage discovery programs, as well as advanced drug candidates in the areas of diabetes and diabetic complications, inflammatory diseases, neuroscience, oncology, and pain and anti-infective. Evotec SE has a strategic drug discovery and development partnership with Celgene Corporation; strategic research alliance with Novo Nordisk A/S and Celmatix Inc.; collaboration with Sanofi; research collaboration with Almirall; research alliance with Ferring Pharmaceuticals; strategic collaboration with Centogene; collaboration with Immuneering; drug discovery alliance with LEO Pharma; strategic partnerships with the Sensyne Health plc, Oxford University Innovation Ltd., Secarna Pharmaceuticals GmbH & Co. KG, and Oxford Sciences Innovation to fund LAB10x; and drug discovery and development partnership with Aeovian Pharmaceuticals Inc. The company also has a collaboration with Indivumed GmbH; a partnership with Celmatix Inc.; a strategic collaboration with Ildong Pharmaceutical Co., Ltd.; a drug discovery research collaboration with HitGen Inc.; a partnership with Rappta Therapeutics; and a partnership with Sartorius. The company was founded in 1993 and is headquartered in Hamburg, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Hamburg"
    },
    "FMCQF": {
        "short_name": "FRESENIUS MEDICAL CARE AG & CO ",
        "long_name": "Fresenius Medical Care AG & Co. KGaA",
        "summary": "Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides pharmacy services, vascular, cardiovascular, endovascular specialty, hospitalist, emergency, intensivist, medical cost management, ambulatory surgery center, health plan, urgent care, physician nephrology and cardiology, and ambulant treatment services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2019, it operated 3,994 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Bad Homburg"
    },
    "FME.DE": {
        "short_name": "FRESEN.MED.CARE KGAA O.N.",
        "long_name": "Fresenius Medical Care AG & Co. KGaA",
        "summary": "Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides pharmacy services, vascular, cardiovascular, endovascular specialty, hospitalist, emergency, intensivist, medical cost management, ambulatory surgery center, health plan, urgent care, physician nephrology and cardiology, and ambulant treatment services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2019, it operated 3,994 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Bad Homburg"
    },
    "FME.F": {
        "short_name": "FRESEN.MED.CARE KGAA O.N.",
        "long_name": "Fresenius Medical Care AG & Co. KGaA",
        "summary": "Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides pharmacy services, vascular, cardiovascular, endovascular specialty, hospitalist, emergency, intensivist, medical cost management, ambulatory surgery center, health plan, urgent care, physician nephrology and cardiology, and ambulant treatment services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2019, it operated 3,994 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Bad Homburg"
    },
    "FMEA.F": {
        "short_name": "FRESENIUS MD.CARE ADR 1/2",
        "long_name": "Fresenius Medical Care AG & Co. KGaA",
        "summary": "Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides pharmacy services, vascular, cardiovascular, endovascular specialty, hospitalist, emergency, intensivist, medical cost management, ambulatory surgery center, health plan, urgent care, physician nephrology and cardiology, and ambulant treatment services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2019, it operated 3,994 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Bad Homburg"
    },
    "FMS": {
        "short_name": "Fresenius Medical Care AG",
        "long_name": "Fresenius Medical Care AG & Co. KGaA",
        "summary": "Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides pharmacy services, vascular, cardiovascular, endovascular specialty, hospitalist, emergency, intensivist, medical cost management, ambulatory surgery center, health plan, urgent care, physician nephrology and cardiology, and ambulant treatment services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2019, it operated 3,994 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "Germany",
        "city": "Bad Homburg"
    },
    "FRE.DE": {
        "short_name": "FRESENIUS SE+CO.KGAA O.N.",
        "long_name": "Fresenius SE & Co. KGaA",
        "summary": "Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment specializes in the therapy and care of chronically and critically ill patients. This segment offers IV drugs, including intravenously administered generic anesthetics, analgesics, anti-infectives, and drugs for the treatment of oncological and other critical diseases; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; infusion and nutrition pumps, as well as consumables; and products that are used in the collection and processing of blood components, as well as in transfusion medicine and cell therapy. As of December 31, 2019, this segment operated 86 hospitals, approximately 125 outpatient clinics, and 8 prevention centers. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. Fresenius SE & Co. KGaA has a strategic partnership with Humacyte Inc. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der H\u00c3\u00b6he, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Bad Homburg vor der H\u00c3\u00b6he"
    },
    "FRE.F": {
        "short_name": "FRESENIUS SE+CO.KGAA O.N.",
        "long_name": "Fresenius SE & Co. KGaA",
        "summary": "Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment specializes in the therapy and care of chronically and critically ill patients. This segment offers IV drugs, including intravenously administered generic anesthetics, analgesics, anti-infectives, and drugs for the treatment of oncological and other critical diseases; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; infusion and nutrition pumps, as well as consumables; and products that are used in the collection and processing of blood components, as well as in transfusion medicine and cell therapy. As of December 31, 2019, this segment operated 86 hospitals, approximately 125 outpatient clinics, and 8 prevention centers. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. Fresenius SE & Co. KGaA has a strategic partnership with Humacyte Inc. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der H\u00c3\u00b6he, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Bad Homburg vor der H\u00c3\u00b6he"
    },
    "FREA.F": {
        "short_name": "FRESENIUS SE+CO. ADR 1/4",
        "long_name": "Fresenius SE & Co. KGaA",
        "summary": "Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment specializes in the therapy and care of chronically and critically ill patients. This segment offers IV drugs, including intravenously administered generic anesthetics, analgesics, anti-infectives, and drugs for the treatment of oncological and other critical diseases; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; infusion and nutrition pumps, as well as consumables; and products that are used in the collection and processing of blood components, as well as in transfusion medicine and cell therapy. As of December 31, 2019, this segment operated 86 hospitals, approximately 125 outpatient clinics, and 8 prevention centers. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. Fresenius SE & Co. KGaA has a strategic partnership with Humacyte Inc. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der H\u00c3\u00b6he, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Bad Homburg vor der H\u00c3\u00b6he"
    },
    "FREN.MX": {
        "short_name": "FRESENIUS SE&CO KGAA",
        "long_name": "Fresenius SE & Co. KGaA",
        "summary": "Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment specializes in the therapy and care of chronically and critically ill patients. This segment offers IV drugs, including intravenously administered generic anesthetics, analgesics, anti-infectives, and drugs for the treatment of oncological and other critical diseases; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; infusion and nutrition pumps, as well as consumables; and products that are used in the collection and processing of blood components, as well as in transfusion medicine and cell therapy. As of December 31, 2019, this segment operated 86 hospitals, approximately 125 outpatient clinics, and 8 prevention centers. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. Fresenius SE & Co. KGaA has a strategic partnership with Humacyte Inc. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der H\u00c3\u00b6he, Germany.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "Germany",
        "city": "Bad Homburg vor der H\u00c3\u00b6he"
    },
    "FSNUF": {
        "short_name": "FRESENIUS SE&CO KGAA",
        "long_name": "Fresenius SE & Co. KGaA",
        "summary": "Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment specializes in the therapy and care of chronically and critically ill patients. This segment offers IV drugs, including intravenously administered generic anesthetics, analgesics, anti-infectives, and drugs for the treatment of oncological and other critical diseases; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; infusion and nutrition pumps, as well as consumables; and products that are used in the collection and processing of blood components, as well as in transfusion medicine and cell therapy. As of December 31, 2019, this segment operated 86 hospitals, approximately 125 outpatient clinics, and 8 prevention centers. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. Fresenius SE & Co. KGaA has a strategic partnership with Humacyte Inc. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der H\u00c3\u00b6he, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Bad Homburg vor der H\u00c3\u00b6he"
    },
    "FSNUY": {
        "short_name": "FRESENIUS SE&CO KGAA",
        "long_name": "Fresenius SE & Co. KGaA",
        "summary": "Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment specializes in the therapy and care of chronically and critically ill patients. This segment offers IV drugs, including intravenously administered generic anesthetics, analgesics, anti-infectives, and drugs for the treatment of oncological and other critical diseases; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; infusion and nutrition pumps, as well as consumables; and products that are used in the collection and processing of blood components, as well as in transfusion medicine and cell therapy. As of December 31, 2019, this segment operated 86 hospitals, approximately 125 outpatient clinics, and 8 prevention centers. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. Fresenius SE & Co. KGaA has a strategic partnership with Humacyte Inc. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der H\u00c3\u00b6he, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Bad Homburg vor der H\u00c3\u00b6he"
    },
    "FYB.DE": {
        "short_name": "FORMYCON AG",
        "long_name": "Formycon AG",
        "summary": "Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis 1, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases that has completed Phase III clinical trials; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase I clinical trial; and FYB203, a biosimilar candidate for Eylea 3, like Lucentis, Eylea, used to treat neovascular age-related macular degeneration and other eye diseases. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Planegg"
    },
    "FYB.F": {
        "short_name": "FORMYCON AG",
        "long_name": "Formycon AG",
        "summary": "Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis 1, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases that has completed Phase III clinical trials; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase I clinical trial; and FYB203, a biosimilar candidate for Eylea 3, like Lucentis, Eylea, used to treat neovascular age-related macular degeneration and other eye diseases. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Planegg"
    },
    "GME.DE": {
        "short_name": "GERATHERM O.N.",
        "long_name": "Geratherm Medical AG",
        "summary": "Geratherm Medical AG operates as a medical technology company in Germany. It operates through Healthcare Diagnostic, Medical Warming Systems, Cardio/Stroke, and Respiratory segments. The Healthcare Diagnostic segment primarily offers clinical thermometers; blood pressure monitors; and self-test diagnostic products for women, including pregnancy tests, chlamydia tests, ovulation tract solutions, and pH tests. The Medical Warming Systems segment provides warming systems under the UniqueTemp and Unique Resc+ brand names to maintain body temperature during operations and in rescue situations; and nomag IC, an incubator system for premature and newborn infants under the LMT brand. The Cardio/Stroke segment offers stroke risk analysis products for the detection of atrial fibrillation used in preventing strokes. The Respiratory segment develops and manufactures products under the Spirostik and Spirostik Complete names, principally for the pulmonary and cardiopulmonary function diagnostics. The company markets its products through pharmacies, hospitals, and clinics. Geratherm Medical AG exports its products to Europe, South America, the Middle East, the United States, and internationally. The company is headquartered in Geschwenda, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Geschwenda"
    },
    "GME.F": {
        "short_name": "GERATHERM O.N.",
        "long_name": "Geratherm Medical AG",
        "summary": "Geratherm Medical AG operates as a medical technology company in Germany. It operates through Healthcare Diagnostic, Medical Warming Systems, Cardio/Stroke, and Respiratory segments. The Healthcare Diagnostic segment primarily offers clinical thermometers; blood pressure monitors; and self-test diagnostic products for women, including pregnancy tests, chlamydia tests, ovulation tract solutions, and pH tests. The Medical Warming Systems segment provides warming systems under the UniqueTemp and Unique Resc+ brand names to maintain body temperature during operations and in rescue situations; and nomag IC, an incubator system for premature and newborn infants under the LMT brand. The Cardio/Stroke segment offers stroke risk analysis products for the detection of atrial fibrillation used in preventing strokes. The Respiratory segment develops and manufactures products under the Spirostik and Spirostik Complete names, principally for the pulmonary and cardiopulmonary function diagnostics. The company markets its products through pharmacies, hospitals, and clinics. Geratherm Medical AG exports its products to Europe, South America, the Middle East, the United States, and internationally. The company is headquartered in Geschwenda, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Geschwenda"
    },
    "GXI.DE": {
        "short_name": "GERRESHEIMER AG",
        "long_name": "Gerresheimer AG",
        "summary": "Gerresheimer AG, together with its subsidiaries, manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through three divisions; Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices. It also provides containers for the delivery of tablets and powders, liquid dosages, ophthalmic and rhinological applications, parenteral packaging applications, oral prescription medications, and cosmetics. The Primary Packaging Glass division offers glass primary packaging for medicines and cosmetics, such as ampoules, cartridges, vials, syrup and dropper bottles, tablet jars, and wide-neck jars, as well as injection, infusion, and transfusion bottles; flacons and pots for fragrances, deodorants, and skin care and decorative cosmetics; and bottles and jars for spirits and food. The Advanced Technologies division develops drug delivery products and platforms, such as micro pumps, which are used to self-administer medication for diabetes or Parkinson's for pharmaceutical and biotech customers. The company was founded in 1864 and is headquartered in D\u00c3\u00bcsseldorf, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "D\u00c3\u00bcsseldorf"
    },
    "GXI.F": {
        "short_name": "GERRESHEIMER AG",
        "long_name": "Gerresheimer AG",
        "summary": "Gerresheimer AG, together with its subsidiaries, manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through three divisions; Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices. It also provides containers for the delivery of tablets and powders, liquid dosages, ophthalmic and rhinological applications, parenteral packaging applications, oral prescription medications, and cosmetics. The Primary Packaging Glass division offers glass primary packaging for medicines and cosmetics, such as ampoules, cartridges, vials, syrup and dropper bottles, tablet jars, and wide-neck jars, as well as injection, infusion, and transfusion bottles; flacons and pots for fragrances, deodorants, and skin care and decorative cosmetics; and bottles and jars for spirits and food. The Advanced Technologies division develops drug delivery products and platforms, such as micro pumps, which are used to self-administer medication for diabetes or Parkinson's for pharmaceutical and biotech customers. The company was founded in 1864 and is headquartered in D\u00c3\u00bcsseldorf, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "D\u00c3\u00bcsseldorf"
    },
    "GXI.VI": {
        "short_name": "GERRESHEIMER AG",
        "long_name": "Gerresheimer AG",
        "summary": "Gerresheimer AG, together with its subsidiaries, manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through three divisions; Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices. It also provides containers for the delivery of tablets and powders, liquid dosages, ophthalmic and rhinological applications, parenteral packaging applications, oral prescription medications, and cosmetics. The Primary Packaging Glass division offers glass primary packaging for medicines and cosmetics, such as ampoules, cartridges, vials, syrup and dropper bottles, tablet jars, and wide-neck jars, as well as injection, infusion, and transfusion bottles; flacons and pots for fragrances, deodorants, and skin care and decorative cosmetics; and bottles and jars for spirits and food. The Advanced Technologies division develops drug delivery products and platforms, such as micro pumps, which are used to self-administer medication for diabetes or Parkinson's for pharmaceutical and biotech customers. The company was founded in 1864 and is headquartered in D\u00c3\u00bcsseldorf, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Germany",
        "city": "D\u00c3\u00bcsseldorf"
    },
    "HAEK.DE": {
        "short_name": "HAEMATO AG  INH O.N.",
        "long_name": "HAEMATO AG",
        "summary": "HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany. The company distributes European import medicinal products; and manufactures and distributes its own generic medicinal products. It provides pharmaceuticals in the areas of oncology, HIV/AIDS, rheumatism, neurology, and cardiovascular diseases; and products for aesthetic treatments. The company also develops and commercializes pharmaceutical, medicinal, and medical engineering products for aesthetic surgery and cosmetic dermatology. It serves wholesalers and pharmacies, as well as doctors and hospitals. The company was founded in 1993 and is headquartered in Sch\u00c3\u00b6nefeld, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Sch\u00c3\u00b6nefeld"
    },
    "HPHA.DE": {
        "short_name": "HEIDELBERG PHARMA AG O.N.",
        "long_name": "Heidelberg Pharma AG",
        "summary": "Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibodies, and specializes in antibody drug conjugates in Germany. It is developing HDP-101 for the treatment of multiple myeloma; PSMA, an ATAC candidate to treat prostate cancer; and CDXX, an ATAC candidate for the treatment of Non-Hodgkin lymphoma and solid/hematological tumors. The company is also developing MGTA-XX-ATACs for HSCs, Conditioning programs for blood cancers, and genetic diseases. In addition, it provides preclinical research services in the field of cancer, as well as inflammatory and autoimmune diseases. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Ladenburg"
    },
    "HPHA.F": {
        "short_name": "HEIDELBERG PHARMA AG O.N.",
        "long_name": "Heidelberg Pharma AG",
        "summary": "Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibodies, and specializes in antibody drug conjugates in Germany. It is developing HDP-101 for the treatment of multiple myeloma; PSMA, an ATAC candidate to treat prostate cancer; and CDXX, an ATAC candidate for the treatment of Non-Hodgkin lymphoma and solid/hematological tumors. The company is also developing MGTA-XX-ATACs for HSCs, Conditioning programs for blood cancers, and genetic diseases. In addition, it provides preclinical research services in the field of cancer, as well as inflammatory and autoimmune diseases. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Ladenburg"
    },
    "IFRX": {
        "short_name": "InflaRx N.V.",
        "long_name": "InflaRx N.V.",
        "summary": "InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Germany",
        "city": "Jena"
    },
    "ILM1.DE": {
        "short_name": "MEDIOS AG  O.N.",
        "long_name": "Medios AG",
        "summary": "Medios AG, together with its subsidiaries, engages in the wholesale of specialty pharmaceutical drugs in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, auto immunology, ophthalmology, and neurology, as well as infectious diseases. The Patient-Specific Therapies segment manufactures drugs for patients on behalf of pharmacies. The company was founded in 2016 and is headquartered in Berlin, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Berlin"
    },
    "IMTX": {
        "short_name": "Immatics N.V.",
        "long_name": "Immatics N.V.",
        "summary": "Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors; and IMA204, an anti-tumor therapy that targets the malignant tumor cell. Its TCR Bispecifics product candidates include IMA401, a cancer testis antigen for the treatment of solid tumor; and IMA402 for the treatment of solid and hematological malignancies. The company also develops IMA101, a multi-target precision immunotherapy; and IMA301, an off-the-shelf ACT. It has a strategic collaboration agreement with GlaxoSmithKline plc to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications; Amgen Inc.; and MorphoSys to develop novel antibody-based therapies against various cancer antigens that are recognized by T cells. Immatics N.V. is headquartered in T\u00c3\u00bcbingen, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Germany",
        "city": "T\u00c3\u00bcbingen"
    },
    "L3D.DE": {
        "short_name": "SYNBIOTIC SE  INH O.N.",
        "long_name": "SynBiotic SE",
        "summary": "SynBiotic SE engages in the development of medicines and over-the-counter wellness products based on cannabinoids. It focuses on synthetic production of cannabinoids, drug development, nutritional supplements, and cosmetic products. The company was formerly known as Ledgertech SE and changed its name to Ledgertech SE. SynBiotic SE based in Munich, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Munich"
    },
    "L3D.DU": {
        "short_name": "SYNBIOTIC SE  INH O.N.",
        "long_name": "SynBiotic SE",
        "summary": "SynBiotic SE engages in the development of medicines and over-the-counter wellness products based on cannabinoids. It focuses on synthetic production of cannabinoids, drug development, nutritional supplements, and cosmetic products. The company was formerly known as Ledgertech SE and changed its name to Ledgertech SE. SynBiotic SE based in Munich, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "DUS",
        "market": "dr_market",
        "country": "Germany",
        "city": "Munich"
    },
    "LIK.DE": {
        "short_name": "LIMES SCHLOSSKLINIK. O.N.",
        "long_name": "LIMES Schlosskliniken AG",
        "summary": "LIMES Schlosskliniken AG operates private hospitals for psychiatry, psychotherapy, and psychosomatics services. It focuses on the treatment of stress-related illnesses, as well as mental and emotional disorders, such as depression, acute burnout, affective disorders, and trauma. The company is headquartered in Cologne, Germany. LIMES Schlosskliniken AG is a subsidiary of G M F Capital Gmbh.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Cologne"
    },
    "LIK.DU": {
        "short_name": "LIMES SCHLOSSKLINIK. O.N.",
        "long_name": "LIMES Schlosskliniken AG",
        "summary": "LIMES Schlosskliniken AG operates private hospitals for psychiatry, psychotherapy, and psychosomatics services. It focuses on the treatment of stress-related illnesses, as well as mental and emotional disorders, such as depression, acute burnout, affective disorders, and trauma. The company is headquartered in Cologne, Germany. LIMES Schlosskliniken AG is a subsidiary of G M F Capital Gmbh.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "DUS",
        "market": "dr_market",
        "country": "Germany",
        "city": "Cologne"
    },
    "LIK.F": {
        "short_name": "LIMES SCHLOSSKLINIK. O.N.",
        "long_name": "LIMES Schlosskliniken AG",
        "summary": "LIMES Schlosskliniken AG operates private hospitals for psychiatry, psychotherapy, and psychosomatics services. It focuses on the treatment of stress-related illnesses, as well as mental and emotional disorders, such as depression, acute burnout, affective disorders, and trauma. The company is headquartered in Cologne, Germany. LIMES Schlosskliniken AG is a subsidiary of G M F Capital Gmbh.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Cologne"
    },
    "M12.DE": {
        "short_name": "M1 KLINIKEN AG  O.N.",
        "long_name": "M1 Kliniken AG",
        "summary": "M1 Kliniken AG, together with its subsidiaries, operates medical centers for aesthetic and plastic surgery in Europe. The company operates through Beauty and Trade segments. It develops and markets pharmaceutical, medical, and medical technology products for aesthetic medicine, plastic surgery, and cosmetic dermatology. The company also engages in the acquisition, development, operation, and sale of real estate, primarily in the health care sector. In addition, it offers its products to private customers, doctors, pharmacies, and wholesalers under the M1 Select and M1 Aesthetics brands. It operates a network of outpatient specialist centers for beauty treatments; and a specialist surgical clinic centres under the M1 Med Beauty, M1 Laser, and M1 Dental brand names. M1 Kliniken AG was founded in 2007 and is based in Berlin, Germany. M1 Kliniken AG operates as a subsidiary of MPH Health Care AG.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Berlin"
    },
    "M12.F": {
        "short_name": "M1 KLINIKEN AG  O.N.",
        "long_name": "M1 Kliniken AG",
        "summary": "M1 Kliniken AG, together with its subsidiaries, operates medical centers for aesthetic and plastic surgery in Europe. The company operates through Beauty and Trade segments. It develops and markets pharmaceutical, medical, and medical technology products for aesthetic medicine, plastic surgery, and cosmetic dermatology. The company also engages in the acquisition, development, operation, and sale of real estate, primarily in the health care sector. In addition, it offers its products to private customers, doctors, pharmacies, and wholesalers under the M1 Select and M1 Aesthetics brands. It operates a network of outpatient specialist centers for beauty treatments; and a specialist surgical clinic centres under the M1 Med Beauty, M1 Laser, and M1 Dental brand names. M1 Kliniken AG was founded in 2007 and is based in Berlin, Germany. M1 Kliniken AG operates as a subsidiary of MPH Health Care AG.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Berlin"
    },
    "M3V.DE": {
        "short_name": "MEVIS MEDICAL SOL.NA O.N.",
        "long_name": "MeVis Medical Solutions AG",
        "summary": "MeVis Medical Solutions AG develops, markets, and sells software for analyzing and evaluating image data to equipment manufacturers of medical devices and providers of medical IT platforms in the United States and Europe. The company's clinical focuses are image-based early detection and diagnosis of epidemiologically important diseases, such as breast, lung, prostate, and colon cancers, as well as neurological disorders. It operates in two segments, Digital Mammography and Other Diagnostics. The Digital Mammography segment develops and markets software products, which support breast diagnostic imaging and intervention. This segment also offers software applications for digital mammography, such as ultrasound, magnetic resonance imaging, and tomosynthesis. The Other Diagnostics segment provides digital radiology products, including magnetic resonance imaging and computer tomography for diseases, such as lung, prostate, and intestinal disorders, as well as general image-based analysis and diagnostics of radiology images. Its services are also used for lung diagnostics and general analysis of MR-image data; and technical visualization, which are used in training, for publication, presentations, and research purposes. This segment also provides interactive online training to enhance the diagnostic capabilities of clinical end customers. The company was founded in 1992 and is based in Bremen, Germany. MeVis Medical Solutions AG operates as a subsidiary of Varex Imaging Deutschland AG.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Bremen"
    },
    "M3V.F": {
        "short_name": "MEVIS MEDICAL SOL.NA O.N.",
        "long_name": "MeVis Medical Solutions AG",
        "summary": "MeVis Medical Solutions AG develops, markets, and sells software for analyzing and evaluating image data to equipment manufacturers of medical devices and providers of medical IT platforms in the United States and Europe. The company's clinical focuses are image-based early detection and diagnosis of epidemiologically important diseases, such as breast, lung, prostate, and colon cancers, as well as neurological disorders. It operates in two segments, Digital Mammography and Other Diagnostics. The Digital Mammography segment develops and markets software products, which support breast diagnostic imaging and intervention. This segment also offers software applications for digital mammography, such as ultrasound, magnetic resonance imaging, and tomosynthesis. The Other Diagnostics segment provides digital radiology products, including magnetic resonance imaging and computer tomography for diseases, such as lung, prostate, and intestinal disorders, as well as general image-based analysis and diagnostics of radiology images. Its services are also used for lung diagnostics and general analysis of MR-image data; and technical visualization, which are used in training, for publication, presentations, and research purposes. This segment also provides interactive online training to enhance the diagnostic capabilities of clinical end customers. The company was founded in 1992 and is based in Bremen, Germany. MeVis Medical Solutions AG operates as a subsidiary of Varex Imaging Deutschland AG.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Bremen"
    },
    "MDG1.DE": {
        "short_name": "MEDIGENE AG NA O.N.",
        "long_name": "Medigene AG",
        "summary": "Medigene AG, a clinical stage immuno-oncology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company operates in two segments, Immunotherapies and Other products. It is developing personalized T cell-based therapies, with a focus on T cell receptor-modified T cells and associated projects, which are in pre-clinical and clinical development. It also focuses on DC vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with bluebird bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Universit\u00c3\u00a9 de Montr\u00c3\u00a9al and Institute for Research in Immunology and Cancer \u00c2\u0097 Commercialization of Research, Canada; and with Cytovant Sciences Co. Ltd. and PHIO Pharmaceuticals Corp. It has operations in Europe, the United States, Greater China, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Munich"
    },
    "MDG1.F": {
        "short_name": "MEDIGENE AG NA O.N.",
        "long_name": "Medigene AG",
        "summary": "Medigene AG, a clinical stage immuno-oncology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company operates in two segments, Immunotherapies and Other products. It is developing personalized T cell-based therapies, with a focus on T cell receptor-modified T cells and associated projects, which are in pre-clinical and clinical development. It also focuses on DC vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with bluebird bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Universit\u00c3\u00a9 de Montr\u00c3\u00a9al and Institute for Research in Immunology and Cancer \u00c2\u0097 Commercialization of Research, Canada; and with Cytovant Sciences Co. Ltd. and PHIO Pharmaceuticals Corp. It has operations in Europe, the United States, Greater China, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Munich"
    },
    "MDG1.VI": {
        "short_name": "MEDIGENE AG",
        "long_name": "Medigene AG",
        "summary": "Medigene AG, a clinical stage immuno-oncology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company operates in two segments, Immunotherapies and Other products. It is developing personalized T cell-based therapies, with a focus on T cell receptor-modified T cells and associated projects, which are in pre-clinical and clinical development. It also focuses on DC vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with bluebird bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Universit\u00c3\u00a9 de Montr\u00c3\u00a9al and Institute for Research in Immunology and Cancer \u00c2\u0097 Commercialization of Research, Canada; and with Cytovant Sciences Co. Ltd. and PHIO Pharmaceuticals Corp. It has operations in Europe, the United States, Greater China, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Germany",
        "city": "Munich"
    },
    "MDGEF": {
        "short_name": "MEDIGENE AG",
        "long_name": "Medigene AG",
        "summary": "Medigene AG, a clinical stage immuno-oncology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company operates in two segments, Immunotherapies and Other products. It is developing personalized T cell-based therapies, with a focus on T cell receptor-modified T cells and associated projects, which are in pre-clinical and clinical development. It also focuses on DC vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with bluebird bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Universit\u00c3\u00a9 de Montr\u00c3\u00a9al and Institute for Research in Immunology and Cancer \u00c2\u0097 Commercialization of Research, Canada; and with Cytovant Sciences Co. Ltd. and PHIO Pharmaceuticals Corp. It has operations in Europe, the United States, Greater China, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Munich"
    },
    "MDQK.HM": {
        "short_name": "MEDINAVI AG  INH. O.N.",
        "long_name": "MediNavi AG",
        "summary": "MediNavi AG owns and operates a platform that allows patients to find doctors and a second doctor's opinion. The company was founded in 2008 and is based in Munich, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "HAM",
        "market": "dr_market",
        "country": "Germany",
        "city": "Munich"
    },
    "MF6.DE": {
        "short_name": "MAGFORCE AG",
        "long_name": "MagForce AG",
        "summary": "MagForce AG operates in the field of nanotechnology-based cancer treatment in Germany and Poland. It offers NanoTherm therapy for the treatment of solid tumors; NanoTherm, a ferrofluid liquid containing superparamagnetic iron oxide nano-particles that could be activated in an alternative magnetic field; NanoPlan, a therapy planning simulation software; and NanoActivator, a magnetic field applicator. The company was founded in 1997 and is headquartered in Berlin, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Berlin"
    },
    "MF6.F": {
        "short_name": "MAGFORCE AG",
        "long_name": "MagForce AG",
        "summary": "MagForce AG operates in the field of nanotechnology-based cancer treatment in Germany and Poland. It offers NanoTherm therapy for the treatment of solid tumors; NanoTherm, a ferrofluid liquid containing superparamagnetic iron oxide nano-particles that could be activated in an alternative magnetic field; NanoPlan, a therapy planning simulation software; and NanoActivator, a magnetic field applicator. The company was founded in 1997 and is headquartered in Berlin, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Berlin"
    },
    "MKGAF": {
        "short_name": "MERCK KGAA",
        "long_name": "MERCK Kommanditgesellschaft auf Aktien",
        "summary": "MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer or multiple sclerosis, infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as carcinoma of the head and neck; prescription drugs for allergen immunotherapy; and fertility treatments. The company also provides life science products and services for the research and applied laboratory applications, as well as for formulating, purifying, manufacturing, and quality-assuring drug therapies of chemical and biological origin; and specialty chemicals, such as liquid crystals and OLED materials for use in displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Intrexon Corporation and Avillion LLP; collaboration with F-star Delta Ltd.; an agreement IAVI and Serum Institute of India Pvt. Ltd. to develop SARS-CoV-2 neutralizing monoclonal antibodies; and collaboration with Iktos for new drug design. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Darmstadt"
    },
    "MKKGY": {
        "short_name": "MERCK KGAA",
        "long_name": "MERCK Kommanditgesellschaft auf Aktien",
        "summary": "MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer or multiple sclerosis, infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as carcinoma of the head and neck; prescription drugs for allergen immunotherapy; and fertility treatments. The company also provides life science products and services for the research and applied laboratory applications, as well as for formulating, purifying, manufacturing, and quality-assuring drug therapies of chemical and biological origin; and specialty chemicals, such as liquid crystals and OLED materials for use in displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Intrexon Corporation and Avillion LLP; collaboration with F-star Delta Ltd.; an agreement IAVI and Serum Institute of India Pvt. Ltd. to develop SARS-CoV-2 neutralizing monoclonal antibodies; and collaboration with Iktos for new drug design. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Darmstadt"
    },
    "MOR": {
        "short_name": "MorphoSys AG",
        "long_name": "MorphoSys AG",
        "summary": "MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; Otilimab, an antibody for rheumatoid arthritis; MOR106, an antibody for inflammatory diseases and atopic dermatitis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "Germany",
        "city": "Planegg"
    },
    "MOR.DE": {
        "short_name": "MORPHOSYS AG O.N.",
        "long_name": "MorphoSys AG",
        "summary": "MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; Otilimab, an antibody for rheumatoid arthritis; MOR106, an antibody for inflammatory diseases and atopic dermatitis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Planegg"
    },
    "MOR.F": {
        "short_name": "MORPHOSYS AG O.N.",
        "long_name": "MorphoSys AG",
        "summary": "MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; Otilimab, an antibody for rheumatoid arthritis; MOR106, an antibody for inflammatory diseases and atopic dermatitis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Planegg"
    },
    "MOR.VI": {
        "short_name": "MORPHOSYS AG",
        "long_name": "MorphoSys AG",
        "summary": "MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; Otilimab, an antibody for rheumatoid arthritis; MOR106, an antibody for inflammatory diseases and atopic dermatitis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Germany",
        "city": "Planegg"
    },
    "MOR2.F": {
        "short_name": "MORPHOSYS AG SP.ADR(TEMP)",
        "long_name": "MorphoSys AG",
        "summary": "MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; Otilimab, an antibody for rheumatoid arthritis; MOR106, an antibody for inflammatory diseases and atopic dermatitis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Planegg"
    },
    "MPSYF": {
        "short_name": "MORPHOSYS",
        "long_name": "MorphoSys AG",
        "summary": "MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; Otilimab, an antibody for rheumatoid arthritis; MOR106, an antibody for inflammatory diseases and atopic dermatitis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Planegg"
    },
    "MRCK.VI": {
        "short_name": "MERCK KGAA",
        "long_name": "MERCK Kommanditgesellschaft auf Aktien",
        "summary": "MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer or multiple sclerosis, infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as carcinoma of the head and neck; prescription drugs for allergen immunotherapy; and fertility treatments. The company also provides life science products and services for the research and applied laboratory applications, as well as for formulating, purifying, manufacturing, and quality-assuring drug therapies of chemical and biological origin; and specialty chemicals, such as liquid crystals and OLED materials for use in displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Intrexon Corporation and Avillion LLP; collaboration with F-star Delta Ltd.; an agreement IAVI and Serum Institute of India Pvt. Ltd. to develop SARS-CoV-2 neutralizing monoclonal antibodies; and collaboration with Iktos for new drug design. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Germany",
        "city": "Darmstadt"
    },
    "MRK.DE": {
        "short_name": "MERCK KGAA O.N.",
        "long_name": "MERCK Kommanditgesellschaft auf Aktien",
        "summary": "MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer or multiple sclerosis, infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as carcinoma of the head and neck; prescription drugs for allergen immunotherapy; and fertility treatments. The company also provides life science products and services for the research and applied laboratory applications, as well as for formulating, purifying, manufacturing, and quality-assuring drug therapies of chemical and biological origin; and specialty chemicals, such as liquid crystals and OLED materials for use in displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Intrexon Corporation and Avillion LLP; collaboration with F-star Delta Ltd.; an agreement IAVI and Serum Institute of India Pvt. Ltd. to develop SARS-CoV-2 neutralizing monoclonal antibodies; and collaboration with Iktos for new drug design. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Darmstadt"
    },
    "MRK.F": {
        "short_name": "MERCK KGAA O.N.",
        "long_name": "MERCK Kommanditgesellschaft auf Aktien",
        "summary": "MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer or multiple sclerosis, infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as carcinoma of the head and neck; prescription drugs for allergen immunotherapy; and fertility treatments. The company also provides life science products and services for the research and applied laboratory applications, as well as for formulating, purifying, manufacturing, and quality-assuring drug therapies of chemical and biological origin; and specialty chemicals, such as liquid crystals and OLED materials for use in displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Intrexon Corporation and Avillion LLP; collaboration with F-star Delta Ltd.; an agreement IAVI and Serum Institute of India Pvt. Ltd. to develop SARS-CoV-2 neutralizing monoclonal antibodies; and collaboration with Iktos for new drug design. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Darmstadt"
    },
    "MRK.MI": {
        "short_name": "MERCK",
        "long_name": "MERCK Kommanditgesellschaft auf Aktien",
        "summary": "MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer or multiple sclerosis, infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as carcinoma of the head and neck; prescription drugs for allergen immunotherapy; and fertility treatments. The company also provides life science products and services for the research and applied laboratory applications, as well as for formulating, purifying, manufacturing, and quality-assuring drug therapies of chemical and biological origin; and specialty chemicals, such as liquid crystals and OLED materials for use in displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Intrexon Corporation and Avillion LLP; collaboration with F-star Delta Ltd.; an agreement IAVI and Serum Institute of India Pvt. Ltd. to develop SARS-CoV-2 neutralizing monoclonal antibodies; and collaboration with Iktos for new drug design. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "MIL",
        "market": "it_market",
        "country": "Germany",
        "city": "Darmstadt"
    },
    "MRKC.SG": {
        "short_name": "Merck KGaA Nam.-Akt.(Sp.ADRs) 1",
        "long_name": "MERCK Kommanditgesellschaft auf Aktien",
        "summary": "MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer or multiple sclerosis, infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as carcinoma of the head and neck; prescription drugs for allergen immunotherapy; and fertility treatments. The company also provides life science products and services for the research and applied laboratory applications, as well as for formulating, purifying, manufacturing, and quality-assuring drug therapies of chemical and biological origin; and specialty chemicals, such as liquid crystals and OLED materials for use in displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions. It has strategic alliances with Pfizer Inc. and GlaxoSmithKline plc; agreement with Intrexon Corporation and Avillion LLP; collaboration with F-star Delta Ltd.; an agreement IAVI and Serum Institute of India Pvt. Ltd. to develop SARS-CoV-2 neutralizing monoclonal antibodies; and collaboration with Iktos for new drug design. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "STU",
        "market": "dr_market",
        "country": "Germany",
        "city": "Darmstadt"
    },
    "NGRC": {
        "short_name": "NATIONAL GRAPHITE CORP",
        "long_name": "National Graphite Corp.",
        "summary": "National Graphite Corp., through its subsidiary, Biotech Development Corp., operates as a biopharmaceutical risk/cost-sharing company. The company collaborates with clinical stage companies that develop new biological entities or new therapeutically platforms for the treatment of various diseases, rare diseases, and diseases with unmet needs. It is developing a drug candidate called ELAFIN, which is a human identic protein for the treatment of postoperative inflammatory complications. National Graphite Corp. has a collaboration agreement with Proteo Inc. for developing ELAFIN. The company was formerly known as Lucky Boy Silver Corporation and changed its name to National Graphite Corp. in May 2012. National Graphite Corp. was founded in 2006 and is based in Duesseldorf, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Duesseldorf"
    },
    "NMI.DE": {
        "short_name": "ALADDIN HLTHC.TECH. O.N.",
        "long_name": "Aladdin Healthcare Technologies SE",
        "summary": "Aladdin Healthcare Technologies SE, through its subsidiary, Aladdin Healthcare Technologies Ltd, develops software solutions for the storage and management of health information using blockchain technology. It specializes in technologies, such as blockchain, machine learning, and artificial intelligence. The company engages in the research and development of Artificial Intelligence Early Diagnosis, an artificial intelligence powered data analysis platform for brain imaging; Health Risk Assessment Platform that assesses the risk of cardiovascular, as well as diabetes and kidney related diseases in patients; and Artificial Intelligence assisted Drug Discovery Platform to identify various small molecule drug compounds with multiple age-related diseases, including Alzheimer's, Parkinson's, and SARS-CoV-2. It uses blockchain, machine learning, artificial intelligence, and advanced predictive data analytics for the early diagnosis of chronic diseases. The company was founded in 2014 and is based in Berlin, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Berlin"
    },
    "NMI.DU": {
        "short_name": "ALADDIN HLTHC.TECH. O.N.",
        "long_name": "Aladdin Healthcare Technologies SE",
        "summary": "Aladdin Healthcare Technologies SE, through its subsidiary, Aladdin Healthcare Technologies Ltd, develops software solutions for the storage and management of health information using blockchain technology. It specializes in technologies, such as blockchain, machine learning, and artificial intelligence. The company engages in the research and development of Artificial Intelligence Early Diagnosis, an artificial intelligence powered data analysis platform for brain imaging; Health Risk Assessment Platform that assesses the risk of cardiovascular, as well as diabetes and kidney related diseases in patients; and Artificial Intelligence assisted Drug Discovery Platform to identify various small molecule drug compounds with multiple age-related diseases, including Alzheimer's, Parkinson's, and SARS-CoV-2. It uses blockchain, machine learning, artificial intelligence, and advanced predictive data analytics for the early diagnosis of chronic diseases. The company was founded in 2014 and is based in Berlin, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "DUS",
        "market": "dr_market",
        "country": "Germany",
        "city": "Berlin"
    },
    "NMI.F": {
        "short_name": "ALADDIN HLTHC.TECH. O.N.",
        "long_name": "Aladdin Healthcare Technologies SE",
        "summary": "Aladdin Healthcare Technologies SE, through its subsidiary, Aladdin Healthcare Technologies Ltd, develops software solutions for the storage and management of health information using blockchain technology. It specializes in technologies, such as blockchain, machine learning, and artificial intelligence. The company engages in the research and development of Artificial Intelligence Early Diagnosis, an artificial intelligence powered data analysis platform for brain imaging; Health Risk Assessment Platform that assesses the risk of cardiovascular, as well as diabetes and kidney related diseases in patients; and Artificial Intelligence assisted Drug Discovery Platform to identify various small molecule drug compounds with multiple age-related diseases, including Alzheimer's, Parkinson's, and SARS-CoV-2. It uses blockchain, machine learning, artificial intelligence, and advanced predictive data analytics for the early diagnosis of chronic diseases. The company was founded in 2014 and is based in Berlin, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Berlin"
    },
    "NN6.DE": {
        "short_name": "NANOREPRO AG",
        "long_name": "NanoRepro AG",
        "summary": "NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. It provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. The company offers rapid diagnostic tests, including allergy, family planning, and preventive healthcare line products; point of care testing products for hospitals and medical practices for detection of HIV, human cardiac Troponin I, D-dimer, streptococci antigen, influenza type A and B antigens, and microalbumin; and immunochromatographic lateral flow tests for the diagnostic detection of biomarkers, as well as rapid SARS-CoV-2 antibody test and corona antigen rapid test. It also provides food supplements for men and women through online shops, as well as through pharmacies. The company is headquartered in Marburg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Marburg"
    },
    "NN6.F": {
        "short_name": "NANOREPRO AG",
        "long_name": "NanoRepro AG",
        "summary": "NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. It provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. The company offers rapid diagnostic tests, including allergy, family planning, and preventive healthcare line products; point of care testing products for hospitals and medical practices for detection of HIV, human cardiac Troponin I, D-dimer, streptococci antigen, influenza type A and B antigens, and microalbumin; and immunochromatographic lateral flow tests for the diagnostic detection of biomarkers, as well as rapid SARS-CoV-2 antibody test and corona antigen rapid test. It also provides food supplements for men and women through online shops, as well as through pharmacies. The company is headquartered in Marburg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Marburg"
    },
    "NXU.DE": {
        "short_name": "NEXUS AG O.N.",
        "long_name": "Nexus AG",
        "summary": "Nexus AG develops and sells software and hardware solutions, and provides IT services, primarily for customers in the health care system worldwide. It operates in two divisions, Healthcare Software and Healthcare Services. The company offers information systems, such as NEXUS/HIS and TESIS for somatic hospitals; NEXUS/PSYCHIATRY for psychiatric institutions; NEXUS/ESKULAP and NEXUS/EPD for somatic and psychiatric institutions; NEXUS/VITA and TESIS VITA for in-vitro clinics; NEXUS/HOME for senior citizen and nursing homes; Emed, a Web-based hospital information system; NEXUS/REHA for rehabilitation facilities; NEXUS/PAT(CH), an administration system for hospitals; NEXUS/GYNECOLOGY for obstetric institutes and gynecology; NEXUS/PATHOLOGY and NEXUS/CYTOLOGY for pathology and cytology institutes; NEXUS/RADIOLOGY, an information and image system for radiology wards and offices; NEXUS/INFORMATION STORE, a management information system for hospitals; NEXUS/QM for quality management in the healthcare system; and NEXUS/CSSD, NEXUS/SPM, and EuroSDS for product sterilization processes in hospitals. Its information systems also comprise NEXUS/INTEGRATIONSERVER for interface management; NEXUS/SPECIAL DIAGNOSTICS and Clinic WinData for medical diagnostics and device integration; NEXUS/OUTPATIENT CARE and Asebis, a homecare solution; NEXUS/ARCHIVE and PEGASOS, an archiving and process management system; NEXUS/SWITSPOT software solutions; ASS.TEC for process and HR consulting in SAP environment; highsystemNET life cycle client management; CREATIVE OM, CRM solution; and NEXUS/Cloud IT, outsourcing solutions in healthcare. In addition, the company offers NEXUS/MOBILE for device management, app monitoring, communication, and HIS integration, as well as NEXUS/ECM, NEXUS/E&L, NEXUS/CHILI, NEXUS/PDMS, NEXUS/RIS/PACS, and NEXUS/FOODCARE. NEXUS AG is headquartered in Donaueschingen, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Donaueschingen"
    },
    "NXU.F": {
        "short_name": "NEXUS AG O.N.",
        "long_name": "Nexus AG",
        "summary": "Nexus AG develops and sells software and hardware solutions, and provides IT services, primarily for customers in the health care system worldwide. It operates in two divisions, Healthcare Software and Healthcare Services. The company offers information systems, such as NEXUS/HIS and TESIS for somatic hospitals; NEXUS/PSYCHIATRY for psychiatric institutions; NEXUS/ESKULAP and NEXUS/EPD for somatic and psychiatric institutions; NEXUS/VITA and TESIS VITA for in-vitro clinics; NEXUS/HOME for senior citizen and nursing homes; Emed, a Web-based hospital information system; NEXUS/REHA for rehabilitation facilities; NEXUS/PAT(CH), an administration system for hospitals; NEXUS/GYNECOLOGY for obstetric institutes and gynecology; NEXUS/PATHOLOGY and NEXUS/CYTOLOGY for pathology and cytology institutes; NEXUS/RADIOLOGY, an information and image system for radiology wards and offices; NEXUS/INFORMATION STORE, a management information system for hospitals; NEXUS/QM for quality management in the healthcare system; and NEXUS/CSSD, NEXUS/SPM, and EuroSDS for product sterilization processes in hospitals. Its information systems also comprise NEXUS/INTEGRATIONSERVER for interface management; NEXUS/SPECIAL DIAGNOSTICS and Clinic WinData for medical diagnostics and device integration; NEXUS/OUTPATIENT CARE and Asebis, a homecare solution; NEXUS/ARCHIVE and PEGASOS, an archiving and process management system; NEXUS/SWITSPOT software solutions; ASS.TEC for process and HR consulting in SAP environment; highsystemNET life cycle client management; CREATIVE OM, CRM solution; and NEXUS/Cloud IT, outsourcing solutions in healthcare. In addition, the company offers NEXUS/MOBILE for device management, app monitoring, communication, and HIS integration, as well as NEXUS/ECM, NEXUS/E&L, NEXUS/CHILI, NEXUS/PDMS, NEXUS/RIS/PACS, and NEXUS/FOODCARE. NEXUS AG is headquartered in Donaueschingen, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Donaueschingen"
    },
    "PA8.DE": {
        "short_name": "PAION O.N",
        "long_name": "Paion AG",
        "summary": "Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for out-patient and hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in final stage of clinical development for use in procedural sedation, as well as in other indications, such as general anesthesia and intensive care unit sedation. It has partnerships and license agreements with Cosmo Pharmaceuticals, Yichang Humanwell, R-Pharm, TR-Pharm, Hana Pharm, Pharmascience, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Aachen"
    },
    "PA8.F": {
        "short_name": "PAION O.N",
        "long_name": "Paion AG",
        "summary": "Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for out-patient and hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in final stage of clinical development for use in procedural sedation, as well as in other indications, such as general anesthesia and intensive care unit sedation. It has partnerships and license agreements with Cosmo Pharmaceuticals, Yichang Humanwell, R-Pharm, TR-Pharm, Hana Pharm, Pharmascience, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Aachen"
    },
    "PHH2.F": {
        "short_name": "PAUL HARTMANN AG NA O.N.",
        "long_name": "Paul Hartmann AG",
        "summary": "Paul Hartmann AG manufactures and sells medical and care products in Europe, Africa, Asia, and Oceania. It offers disinfectant products for hands, surface, and instruments; cleaning, skin care, and skin antisepsis products, as well as Sterillium, a hand disinfectant; incontinence management products; and personal healthcare products, such as diagnostic devices and first aid products. The company also provides single-use and pre-surgical products, disposable surgical gloves, clothing and gowns, and disposable drapes for use in operating theatres, treatment rooms, and wards; and wound management solutions, including traditional compresses, bandages, hydro therapy products. In addition, it markets body care, dietary supplements, and herbal medicinal products; and distributes private-label products, such as cotton/cosmetic, medical, and baby and home care products. The company was founded in 1818 and is based in Heidenheim, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Heidenheim"
    },
    "PUS.MU": {
        "short_name": "PULSION ST O.N.",
        "long_name": "PULSION Medical Systems SE",
        "summary": "PULSION Medical Systems SE engages in the development and sale of monitoring systems and disposables for diagnosis and treatment of patients worldwide. The company offers its principal products in the fields of anesthesia, surgical and internal intensive care medicine, and cardiology, as well as ophthalmology and tumor therapy. PULSION Medical Systems SE was founded in 1990 and is headquartered in Feldkirchen, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "Germany",
        "city": "Feldkirchen"
    },
    "QBI.HM": {
        "short_name": "Q2M MGMT.BERAT.AG",
        "long_name": "Q2M Managementberatung AG",
        "summary": "Q2M Managementberatung AG provides provides management consultancy services. It offers succession planning, interim management, and operational implementation services. The company is based in Mannheim, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HAM",
        "market": "dr_market",
        "country": "Germany",
        "city": "Mannheim"
    },
    "RHK.DE": {
        "short_name": "RHOEN-KLINIKUM O.N.",
        "long_name": "RH\u00d6N-KLINIKUM Aktiengesellschaft",
        "summary": "RH\u00c3\u0096N-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services, including rehabilitation of cardiovascular patients, hand surgery, neurological, psychosomatic, addiction therapy facilities, ophthalmology, trauma surgery, dentistry, thoracic, pulmonary, vascular, tumors, neurological conditions, and treatment of spinal column, joints, and heart diseases. As of December 31, 2019, it operated 8 hospitals and 5,312 beds/places at 5 medical sites. The company is headquartered in Bad Neustadt an der Saale, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Bad Neustadt an der Saale"
    },
    "RHK.F": {
        "short_name": "RHOEN-KLINIKUM O.N.",
        "long_name": "RH\u00d6N-KLINIKUM Aktiengesellschaft",
        "summary": "RH\u00c3\u0096N-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services, including rehabilitation of cardiovascular patients, hand surgery, neurological, psychosomatic, addiction therapy facilities, ophthalmology, trauma surgery, dentistry, thoracic, pulmonary, vascular, tumors, neurological conditions, and treatment of spinal column, joints, and heart diseases. As of December 31, 2019, it operated 8 hospitals and 5,312 beds/places at 5 medical sites. The company is headquartered in Bad Neustadt an der Saale, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Bad Neustadt an der Saale"
    },
    "RHK.VI": {
        "short_name": "RHOEN-KLINIKUM AG",
        "long_name": "RH\u00d6N-KLINIKUM Aktiengesellschaft",
        "summary": "RH\u00c3\u0096N-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services, including rehabilitation of cardiovascular patients, hand surgery, neurological, psychosomatic, addiction therapy facilities, ophthalmology, trauma surgery, dentistry, thoracic, pulmonary, vascular, tumors, neurological conditions, and treatment of spinal column, joints, and heart diseases. As of December 31, 2019, it operated 8 hospitals and 5,312 beds/places at 5 medical sites. The company is headquartered in Bad Neustadt an der Saale, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "VIE",
        "market": "at_market",
        "country": "Germany",
        "city": "Bad Neustadt an der Saale"
    },
    "RHKU.F": {
        "short_name": "RHOEN-KLINIK.UNSP.ADR 1/2",
        "long_name": "RH\u00d6N-KLINIKUM Aktiengesellschaft",
        "summary": "RH\u00c3\u0096N-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services, including rehabilitation of cardiovascular patients, hand surgery, neurological, psychosomatic, addiction therapy facilities, ophthalmology, trauma surgery, dentistry, thoracic, pulmonary, vascular, tumors, neurological conditions, and treatment of spinal column, joints, and heart diseases. As of December 31, 2019, it operated 8 hospitals and 5,312 beds/places at 5 medical sites. The company is headquartered in Bad Neustadt an der Saale, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "Bad Neustadt an der Saale"
    },
    "RKAGY": {
        "short_name": "RHOEN-KLINIKUM AG",
        "long_name": "RH\u00d6N-KLINIKUM Aktiengesellschaft",
        "summary": "RH\u00c3\u0096N-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services, including rehabilitation of cardiovascular patients, hand surgery, neurological, psychosomatic, addiction therapy facilities, ophthalmology, trauma surgery, dentistry, thoracic, pulmonary, vascular, tumors, neurological conditions, and treatment of spinal column, joints, and heart diseases. As of December 31, 2019, it operated 8 hospitals and 5,312 beds/places at 5 medical sites. The company is headquartered in Bad Neustadt an der Saale, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Bad Neustadt an der Saale"
    },
    "SBH.HM": {
        "short_name": "SANGUI BIOTECH INTL",
        "long_name": "Sangui Biotech International, Inc.",
        "summary": "Sangui Biotech International, Inc., through its subsidiary, Sangui BioTech GmbH, develops hemoglobin-based artificial oxygen carriers for use as blood additives, blood volume substitutes, and variant products. The company's artificial oxygen carriers provide oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia, or blood loss, as well as chronic wounds. It also offers nano formulations for the regeneration of skin, including skin moisturization and enhanced skin elasticity; Chitoskin wound pads for supporting wound healing; and Hemospray wound spray, a medical product that is used for the healing of chronic wounds. The company sells its wound spray products under the Granulox brand name primarily in Europe and Mexico; and cosmetics products through internet shop. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "HAM",
        "market": "dr_market",
        "country": "Germany",
        "city": "Hamburg"
    },
    "SGBI": {
        "short_name": "SANGUI BIOTECH INTERNATIONAL",
        "long_name": "Sangui Biotech International, Inc.",
        "summary": "Sangui Biotech International, Inc., through its subsidiary, Sangui BioTech GmbH, develops hemoglobin-based artificial oxygen carriers for use as blood additives, blood volume substitutes, and variant products. The company's artificial oxygen carriers provide oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia, or blood loss, as well as chronic wounds. It also offers nano formulations for the regeneration of skin, including skin moisturization and enhanced skin elasticity; Chitoskin wound pads for supporting wound healing; and Hemospray wound spray, a medical product that is used for the healing of chronic wounds. The company sells its wound spray products under the Granulox brand name primarily in Europe and Mexico; and cosmetics products through internet shop. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Hamburg"
    },
    "SHL.DE": {
        "short_name": "SIEMENS HEALTH.AG NA O.N.",
        "long_name": "Siemens Healthineers AG",
        "summary": "Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and distributes imaging, diagnostic, and advanced therapies products and services to healthcare providers worldwide. The company operates through three segments; Imaging, Diagnostics, and Advanced Therapies. The Imaging segment offers magnetic resonance, computed tomography, X-ray, molecular imaging, and ultrasound systems. The Diagnostics segment provides in-vitro diagnostic products and services to healthcare providers in laboratory, molecular, and point-of-care diagnostics; and workflow solutions and informatics products. The Advanced Therapies segment offers integrated products, solutions, and services for therapy departments of healthcare providers; and robotic-assisted platform for endo-vascular coronary and peripheral vascular interventions. This segment's principal products include angiography systems and mobile C-arms. It also provides customer value chain services, including design, maintenance, operational management, training, and education services. In addition, the company offers equipment performance management, clinical education and e-learning, asset management, and managed departmental services, as well as digital health products and services. The company is headquartered in Erlangen, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "Erlangen"
    },
    "SMMNY": {
        "short_name": "SIEMENS HEALTHINEERS AG",
        "long_name": "Siemens Healthineers AG",
        "summary": "Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and distributes imaging, diagnostic, and advanced therapies products and services to healthcare providers worldwide. The company operates through three segments; Imaging, Diagnostics, and Advanced Therapies. The Imaging segment offers magnetic resonance, computed tomography, X-ray, molecular imaging, and ultrasound systems. The Diagnostics segment provides in-vitro diagnostic products and services to healthcare providers in laboratory, molecular, and point-of-care diagnostics; and workflow solutions and informatics products. The Advanced Therapies segment offers integrated products, solutions, and services for therapy departments of healthcare providers; and robotic-assisted platform for endo-vascular coronary and peripheral vascular interventions. This segment's principal products include angiography systems and mobile C-arms. It also provides customer value chain services, including design, maintenance, operational management, training, and education services. In addition, the company offers equipment performance management, clinical education and e-learning, asset management, and managed departmental services, as well as digital health products and services. The company is headquartered in Erlangen, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Germany",
        "city": "Erlangen"
    },
    "SRT.DE": {
        "short_name": "SARTORIUS AG O.N.",
        "long_name": "Sartorius Aktiengesellschaft",
        "summary": "Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers live cell analysis system, and cell analysis reagents and consumables; cell culture media, including antibody and recombinant protein, viral vaccines, and regenerative medicine media; and multi-parallel, single-use, benchtop, stainless steel, microbial, and cell culture bioreactors, as well as cell culture expansion systems and software applications for bioreactors. It also provides lab filtration and purification devices; sterile and virus filtration, crossflow filtration, harvesting, prefiltration, membrane chromatography, air/gas filtration, and integrity testing devices; and liquid storage and shipping, freeze and thaw, mixing, proven integrity, transferring and sampling, connecting and disconnecting, and final filling management products. In addition, the company offers process control and data analytics products, such as process analyzers, automation modules, and data analytics and chemometrics; and microbiology products, and lab water purification systems. Further, it provides lab balances, mass comparators and metrology, moisture analyzers, specialty weighing solutions, weighing accessories, weights/weight sets, paint mixing solutions, and OEM weigh cells; and OEM membrane and device, pipetting and dispensing, and connectivity solutions. Additionally, the company offers bioprocess development engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, cannabis testing, food and beverage, environmental, and paint mixing industries. Sartorius Aktiengesellschaft and Evotec SE has a partnership with Curexsys GmbH on iPSC-based therapeutic exosome approach. The company was founded in 1870 and is headquartered in G\u00c3\u00b6ttingen, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "G\u00c3\u00b6ttingen"
    },
    "SRT.F": {
        "short_name": "SARTORIUS AG O.N.",
        "long_name": "Sartorius Aktiengesellschaft",
        "summary": "Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers live cell analysis system, and cell analysis reagents and consumables; cell culture media, including antibody and recombinant protein, viral vaccines, and regenerative medicine media; and multi-parallel, single-use, benchtop, stainless steel, microbial, and cell culture bioreactors, as well as cell culture expansion systems and software applications for bioreactors. It also provides lab filtration and purification devices; sterile and virus filtration, crossflow filtration, harvesting, prefiltration, membrane chromatography, air/gas filtration, and integrity testing devices; and liquid storage and shipping, freeze and thaw, mixing, proven integrity, transferring and sampling, connecting and disconnecting, and final filling management products. In addition, the company offers process control and data analytics products, such as process analyzers, automation modules, and data analytics and chemometrics; and microbiology products, and lab water purification systems. Further, it provides lab balances, mass comparators and metrology, moisture analyzers, specialty weighing solutions, weighing accessories, weights/weight sets, paint mixing solutions, and OEM weigh cells; and OEM membrane and device, pipetting and dispensing, and connectivity solutions. Additionally, the company offers bioprocess development engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, cannabis testing, food and beverage, environmental, and paint mixing industries. Sartorius Aktiengesellschaft and Evotec SE has a partnership with Curexsys GmbH on iPSC-based therapeutic exosome approach. The company was founded in 1870 and is headquartered in G\u00c3\u00b6ttingen, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Germany",
        "city": "G\u00c3\u00b6ttingen"
    },
    "SRT3.DE": {
        "short_name": "SARTORIUS AG VZO O.N.",
        "long_name": "Sartorius Aktiengesellschaft",
        "summary": "Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers live cell analysis system, and cell analysis reagents and consumables; cell culture media, including antibody and recombinant protein, viral vaccines, and regenerative medicine media; and multi-parallel, single-use, benchtop, stainless steel, microbial, and cell culture bioreactors, as well as cell culture expansion systems and software applications for bioreactors. It also provides lab filtration and purification devices; sterile and virus filtration, crossflow filtration, harvesting, prefiltration, membrane chromatography, air/gas filtration, and integrity testing devices; and liquid storage and shipping, freeze and thaw, mixing, proven integrity, transferring and sampling, connecting and disconnecting, and final filling management products. In addition, the company offers process control and data analytics products, such as process analyzers, automation modules, and data analytics and chemometrics; and microbiology products, and lab water purification systems. Further, it provides lab balances, mass comparators and metrology, moisture analyzers, specialty weighing solutions, weighing accessories, weights/weight sets, paint mixing solutions, and OEM weigh cells; and OEM membrane and device, pipetting and dispensing, and connectivity solutions. Additionally, the company offers bioprocess development engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, cannabis testing, food and beverage, environmental, and paint mixing industries. Sartorius Aktiengesellschaft and Evotec SE has a partnership with Curexsys GmbH on iPSC-based therapeutic exosome approach. The company was founded in 1870 and is headquartered in G\u00c3\u00b6ttingen, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "GER",
        "market": "de_market",
        "country": "Germany",
        "city": "G\u00c3\u00b6ttingen"
    },
    "VVY.AS": {
        "short_name": "VIVORYON",
        "long_name": "Vivoryon Therapeutics N.V.",
        "summary": "Vivoryon Therapeutics AG, a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease; and for the treatment of cancer. Its preclinical development products is PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor for the treatment of cancer. In addition, the company is developing a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Vivoryon Therapeutics AG has a research collaboration agreement with University Medical Center Schleswig-Holstein to discover and develop therapeutics in cancer immunotherapy; collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology. The company was formerly known as Probiodrug AG and changed its name to Vivoryon Therapeutics AG in June 2019. Vivoryon Therapeutics AG was founded in 1997 and is headquartered in Halle, Germany.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "AMS",
        "market": "nl_market",
        "country": "Germany",
        "city": "Halle"
    }
}